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Abstract 
The Molecular Mechanism of Replication Independent Repair of DNA Interstrand Crosslinks 
Niyo Kato 
 
DNA interstrand crosslinks (ICLs) are a potent type of DNA damage that arise as a 
consequence of normal cell metabolism. By covalently linking opposing strands of the double 
helix, ICLs block essential DNA transactions such as replication, transcription, and 
recombination. If unrepaired, or incorrectly repaired, ICLs can lead to gross genome instability 
and cell death. This cytotoxicity has been exploited in the clinic, where ICL inducing drugs are 
among the oldest and most widely prescribed anti-cancer therapies. However, acquired resistance 
is a significant limitation of these drugs, and the mechanism by which this occurs remains largely 
elusive.  
In order to develop more effective ICL-based therapies, it is imperative to first fully elucidate 
how healthy cells respond to and repair ICLs. Moreover, better understanding ICL repair 
mechanisms is necessary to fully unravel the complex DNA repair networks that govern genomic 
integrity, and understand the physiology of diseases such as Fanconi Anemia, which result from 
the inability to efficiently repair ICL lesions.  
Multiple mechanisms of ICL repair exist, and repair pathway choice is primarily determined 
by the phase of the cell cycle. In proliferating cells, the ICL repair occurs during S-phase, and in 
a process termed “replication coupled repair” (RCR). In contrast, slowly or non-dividing cells 
rely on an alternative modality of repair called “replication independent repair” (RIR). RIR is 
critical for homeostasis and survival in quiescent healthy cells that (for example, neurons) and in 
cycling cells deficient for replication coupled repair proteins (i.e. Fanconi Anemia cells). 
Despite its importance, little is known about RIR. This is due, in part, to the fact that ICL 
repair has been primarily studied in systems, such as cultured cells, that favor RCR and are 
therefore bias against RIR. More recently, non-replicating Xenopus cell-free extracts has 
emerged as a powerful system to study RIR. This system faithfully recapitulates RIR and has 
been instrumental in identifying DNA polymerase kappa (Pol κ) and the eukaryotic sliding 
clamp, proliferating cell nuclear antigen (PCNA), as two critical RIR factors. However, other 
important RIR factors are yet to be identified.  
ICL repair is unique among DNA repair pathways as it harnesses proteins from diverse DNA 
repair pathways including, Base Excision Repair (BER), Nucleotide Excision Repair (NER), 
Mismatch Repair (MMR), and Double Strand Break Repair (DSBR). Chapter 1 provides an 
overview of these pathways including the types of DNA damage that each pathway responds to, 
key steps of the repair process, and the corresponding proteins that are involved. This chapter 
provides context for the rest of the thesis in which I explore the contribution of multiple DNA 
repair proteins on the repair of ICL lesions.  
In Chapter 2, I detail our studies assessing the contribution of the MMR machinery to RIR. 
We show that the mismatch repair sensor, MutSa complex (MSH2-MSH6), is critical for ICL 
recognition, and the stepwise recruitment of other MMR proteins including MutLa (MLH1-
PMS2) and EXO1. In this chapter, I also investigate how ICL structure influences repair. I find 
that more distorting ICLs use an MMR-dependent ICL repair mechanism, while less distorting 
ICLs are repaired MMR-independently (see also Appendix A), or not repaired at all. Appendix B 
further explores the contribution of the MMR pathway on ICL repair in mammalian cells.  
Finally, in Appendix C and D we provide further evidence that RIR is fundamentally distinct 
from replication coupled ICL repair, as depletion of key RCR proteins from our extracts yields 
no phenotype.  
I summarize all of these findings in Chapter 3, and discuss their implications to the DNA 
repair field as well as the clinic, where crosslinker drugs remain a mainstay in the treatment of 
cancer. 
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DNA Damage Types and DNA Repair Pathways 
 
DNA is the carrier of genetic information for all living organisms. Its integrity is 
essential to allow for cellular and organismal homeostasis, and to ensure the transmission 
of intact genetic material during reproduction. DNA, however, undergoes spontaneous 
rearrangement, and is also challenged by various endogenous reactive species and 
exogenous sources of damage including irradiation and exposure to chemical mutagens 
(summarized in Table 1-1, and illustrated in Figure 1-1).  
It is estimated that on average, tens of thousands of damaged lesions are incurred per 
mammalian cell per day (Ciccia and Elledge, 2010). These lesions vary from 
ribonucleotide incorporation or single-base alterations, to more complex damage that 
involves both strands of the DNA helix (summarized in Table 1-1, and illustrated in 
Figure 1-1). Generally speaking, simpler DNA lesions that involve a single base are less 
distorting, while bulkier adducts that involve multiple bases or larger chemical 
modifications to DNA bases can significantly distort the DNA molecule. 
Types of DNA damage that occur spontaneously at a single base include replication 
errors, which result in base-base mismatches, or bases that undergo spontaneous 
depurination or deamination, that result in the generation of abasic sites and base 
transitions. DNA bases can also be chemically modified by reactive oxygen and nitrogen 
species. Bulkier DNA adducts such as pyrimidine dimers (a linkage between neighboring 
thymine bases) arise as a result of sun exposure, a common source of UV irradiation. 
Large monoadducts and intrastrand crosslinks occur when DNA reacts with endogenous 
aldehydes that are produced during cellular metabolism. Aldehydes, and other 
bifunctional reactive chemicals can react with opposing strands of the double helix, to 
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generate DNA interstrand crosslinks (ICLs). Finally, DNA strand breaks, either single or 
double stranded, are generated in many ways, including exposure to ionizing radiation or 
as intermediates during multiple DNA repair pathways. 
When unrepaired or incorrectly repaired, DNA damage can lead to mutation and 
chromosome aberrations, which in turn cause aging, disease, or death. Cells have evolved 
mechanisms to quickly and efficiently identify and repair DNA damage. This 
sophisticated network of mechanisms is collectively termed the DNA damage response 
(DDR) (reviewed in Ciccia and Elledge, 2010). Many pathways of the DDR have been 
mechanistically described, and include: Base Excision Repair (BER), Nucleotide 
Excision Repair (NER), Mismatch Repair (MMR), and Double Strand Break Repair 
(DSBR). Each of these pathways have specialized to respond to specific types/classes of 
DNA damage. Key aspects of these pathways are highly conserved from bacteria to 
humans, and for the sake of brevity, only the canonical mammalian DNA repair proteins 
and pathways will be described here. Emphasis is placed on DNA ICLs and their repair, 
as these lesions are the primarily focus of this thesis. 
 
Base Excision Repair 
 
The Base Excision Repair (BER) pathway removes small alterations at single DNA 
bases that have been oxidized or deaminated. While these lesions are minimally 
distorting to the DNA, they can be mutagenic and/or cytotoxic to cells.  
Damage sensing in the BER pathway is initiated by one of at least 11 damage-specific 
DNA glycosylases. Glycosylases are enzymes that recognize and excise damaged DNA 
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bases. Nucleobase removal results in an abasic site (Ap site), which must be further 
processed. In canonical BER, APE1 (apurinic/apyrimidinic endonuclease), generates a 
single strand break 5’ to the original damaged base, which allows for the replacement and 
repair of the damaged nucleotide by translesion synthesis polymerase beta (Pol β) and 
XRCC1-Ligase III (X-ray repair cross-complementing protein 1), which seals the 
remaining nick to restore the DNA to its undamaged state. BER that requires the removal 
of a single base is called “short patched” (illustrated in Figure 1-2), while “long patch” 
BER requires other factors including DNA Polymerase δ (Pol δ), proliferating cell 
nuclear antigen (PCNA), replication factor C (RFC), and replication protein A (RPA) for 
repair, and involves the removal of a longer piece of DNA (Dianov and Hubscher, 2013; 
Jacobs and Schär, 2012; Krokan and Bjoras, 2013). 
 
Nucleotide Excision Repair 
 
Bulkier DNA lesions such a cyclobutane-pyrimidine dimers (CPDs) and 6-4 
pyryimidine pyrimidone photoproducts (6-4PPs) that impart local distortions on the DNA 
helix are repaired by the nucleotide excision repair (NER) pathway. Two branches of 
NER exist: global-genome NER (GG-NER) and transcription-coupled NER (TC-NER). 
In GG-NER (illustrated in Figure 1-2), the DNA damage sensor protein, XPC-HR23 
(xeroderma pigmentosum complementation group C) actively surveils the genome for 
damage, by binding and recognizing regions of the genome that are slightly unwound. 
NER can also be initiated by the transcription machinery (TC-NER). Bulky adducts 
physically block the progression of the transcribing polymerase, and activate repair. 
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Stalled RNA PolII recruits repair proteins including CSA and CSB (Cockayne Syndrome 
Protein A and B) as well as UVSSA-USP7 (UV-stimulated-scaffold-protein A and 
ubiquitin-specific-processing-protease 7), which together dislodge the RNA polymerase 
complex (Marteijn et al., 2014).  
Following damage recognition, TFIIH (transcription initiation factor IIH) complex is 
recruited for damage verification. Two ATP dependent helicases, XPB and XPD, are 
among the ten proteins that make up the TFIIH complex, and are essential for unwinding 
the local DNA region surrounding the damage site (Marteijn et al., 2014; Wood, 2010). 
NER involves two incision events flanking the damage site by the XPF-ERCC1 and 
XPG structure-specific nucleases. XPA and RPA are additional proteins that are required 
to help coordinate repair events and protect the undamaged DNA strand from being 
processed. After incisions, the resulting 22-30 nucleotide gap is subsequently repaired in 
a gap filling reaction by PCNA and a DNA polymerase Pol δ/Pol ε/Pol κ. Nick sealing by 




Base-base mismatches or insertion-deletion loops arise when erroneous incorporation 
of nucleotides occurs during replication. These lesions are efficiently repaired by the 
mismatch repair machinery (MMR), which improves the fidelity of DNA replication by 
2-3 orders of magnitude. 
During MMR, repair is initiated by two partially redundant DNA damage sensor 
proteins MutSa (MSH2-MSH6) and MutSb (MSH2-MSH3). Damage recognition is 
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followed by recruitment of the MutLa (MLH1-PMS2) endonuclease, whose cryptic 
endonuclease is important for MMR. MutLa specifically incises the nascent strand of 
DNA that contains the mispair, signaling for the degradation of the incised strand by the 
EXO1 exonuclease (Jiricny, 2006). It remains unclear how the MMR machinery 
preferentially targets the nascent strand during eukaryotic MMR reaction. It has been 
proposed that strand discontinuities in the nascent strand, either between Okazaki 
fragments on the lagging strand, or nicks/gaps generated during removal of erroneous 
ribonucleotides incorporated during replication might facilitate this process 
(Ghodgaonkar et al., 2013). Whatever the case may be, the gapped repair intermediate 
that remains is filled in by a re-synthesis reaction which involves RPA and DNA 
polymerase δ or ε. 
 
Double Strand Break Repair 
 
Double strand breaks (DSBs) arise endogenously when replication forks collapse, or 
during normal physiological processes such as V(D)J recombination (Symington and 
Gautier, 2011). DSBs also arise upon exposure to ionizing radiation. When unrepaired or 
incorrectly repaired, DSBs can lead to gross chromosomal aberrations.  
Two major pathways respond to and repair DSBs (illustrated in Figure 1-3): 
nonhomologous end joining (NHEJ) and homology directed repair (HDR). NHEJ is the 
predominant mechanisms for repair in non-cycling cells and takes place with no or 
minimal processing of DNA ends. In this process, DNA ends are bound by the Ku70/80 
heterodimer. DNA-bound Ku complex recruit multiple end joining factors including the 
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Ser/Thr kinase DNA-PKcs (DNA-dependent protein kinase catalytic subunit), as well as 
the Artemis endonuclease which participates in end-processing events. The broken DNA 
ends are then ligated by XRCC4 (X-ray repair cross-complementing protein 4) and 
Ligase 4. 
When DSBs arise during S-phase or G2-phase, they can also be repaired by HDR 
mechanisms, including homologous recombination (HR). In this process, damaged ends 
are resected by the MRN (Mre11-Rad50-Nbs1) complex, exonuclease 1 (EXO1), as well 
as BRCA1 (breast cancer 1) and CtIP (CTBP interacting protein). Resected ends are 
initially coated with RPA, then replaced with Rad51 in a Rad52- and BRCA1/2-
dependent manner. Rad51 coated DNA filaments undergo a homology search and use 
template-dependent repair synthesis reaction to restore the integrity of the DNA 
(Symington and Gautier, 2011).  
 
DNA Interstrand Crosslinks and ICL Repair Pathways 
 
DNA interstrand crosslinks (ICLs) are a type of DNA damage that covalently link 
opposing strands of the DNA double helix. ICLs arise endogenously, as a consequence of 
cellular metabolism, but are also induced at high frequency upon exposure to crosslinker-
based chemotherapeutic drugs. Depending on the offending adduct, ICLs can vary greatly 
in their chemical and physical properties, and also in the degree to which they distort the 
DNA. 
Yet, all ICLs are extremely cytotoxic as they physically block cellular processes that 
require helix unwinding, such as replication, recombination, and transcription (Deans and 
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West, 2011). ICLs can also interfere with protein-DNA binding events that are required 
for cell homeostasis, such as transcription factor binding (Martin et al., 2005).  
Cells have evolved multiple mechanisms to sense and remove ICLs from their 
genomes. ICLs are complex chemical lesions as they involve both strands of the DNA 
double helix. This complexity is reflected in the multiple pathways that exist to respond 
to and repair ICL lesions, and the diversity of repair proteins that participate in these 
processes.  
 
Sources of ICLs 
 
Several classes of bifunctional chemicals, both from endogenous and exogenous 
sources, are capable of generating ICL lesions (Table 1-2). Endogenous sources of ICLs 
include various reactive aldehydes that are produced as a byproduct of cellular 
metabolism. For example, formaldehyde, is a ubiquitous endogenous metabolite that is 
generated during oxidative histone demethylation and biosynthesis of purines and amino 
acids. Formaldehyde exposure can also occur through inhalation of tobacco smoke or 
even through consumption of various foods and vegetables. Another endogenous 
aldehyde source is acetaldehyde. Acetaldehyde is produced as a byproduct of ethanol 
oxidation and is also an intermediate of carbohydrate metabolism (Guainazzi and 
Schärer, 2010). Finally, crotonaldehdydes and acroleins are byproduct of lipid 
peroxidation (Deans and West, 2011).  
Some environmental mutagens can also generate ICL lesions. These include 
psoralens and furocoumarins, which are found in plants such a bergamot, celery, and 
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parsley (Deans and West, 2011), as well as Mitomycin C (MMC) a chemical produced by 
the bacteria Streptomyces caespitosus. 
ICLs can be induced at very high frequencies upon exposure to a diverse array of 
crosslinker drugs that have been chemically synthesized. These include nitrogen 
mustards, MMC, and platinum-based drugs. Many of these chemicals are widely and 
successfully used in the clinic as cancer chemotherapeutic drugs.  
Aside from reaction with bifunctional chemicals mentioned above, ICLs can also 
occur spontaneously by chemical rearrangements at abasic DNA sites. Abasic sites (Ap 
sites) exist at a steady-state level of 50,000-200,000 Ap sites / cell (Price et al., 2014) as a 
result of spontaneous depurination or as an intermediate during BER (Dianov and 
Hubscher, 2013). Since Ap sites are electrophilic, they can react with a base on the 
opposing strand of the DNA molecule to generate an ICL (Price et al., 2014).  
 
Structures of ICLs 
 
Each of the crosslinker sources described above, occurring both endogenous and 
exogenously, generates ICLs of varying physical and chemical characteristics. This is in 
part due to the nature of the offending chemical itself, but also a result of the preferential 
base reactivity that many ICL inducing drugs exhibit for DNA (Deans and West, 2011; 
Guainazzi and Schärer, 2010). These features directly influence the local DNA 
conformation to which they are bound, and therefore can also induce various degrees of 
distortion to the double helix (summarized in Table 1-2).  
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Among the crosslinker drugs used in the clinic, the cisplatin-induced ICL is perhaps 
one of the most distorting (Guainazzi and Schärer, 2010). Cisplatin forms preferentially 
between (N7 position) guanine residues at 5’-GpC sequences. The resulting ICL is 
severely distorting as it shortens the distance between the two strands of the double helix, 
and send the two neighboring cytosine residues outward to take on an extra-helical 
conformation (Coste et al., 1999).  
In comparison, mitomycin C (MMC) and nitrogen mustard-ICLs are less distorting 
(Guainazzi and Schärer, 2010). While, MMC ICLs also form between guanine residues, it 
reacts with 5’-CpG sequences. The resulting ICL lesion only slightly widens the minor 
groove. Similarly, nitrogen mustard ICL forms between guanine residues, but at 5’-GNC 
residues and induce only a slight bend in the DNA (Guainazzi et al., 2010). Although Ap-
ICLs are similarly thought to be little-distorting (Johnson et al., 2013; Price et al., 2014), 
the NMR structure has not yet been determined for this type of lesion.  
Of note, many crosslinker sources generate ICLs that are inherently unstable on a 
laboratory timescale, making them difficult to purify and study. For this reason, synthetic 
analogs have been generated (Guainazzi and Schärer, 2010). The malondialdehyde ICL 
lesion has been mimicked in two different conformations using a trimethylene linkage. 
This more stable surrogate links two guanine residues between N2 positions at 5’-GpC 
and 5’-CpG sequences. Both of these synthetic crosslinks are very stable, and their NMR 
structures have been determined (Dooley et al., 2001, 2003). Nitrogen mustard ICLs have 
similarly been mimicked in multiple conformations using synthetic linker compounds 
(Guainazzi et al., 2010; Mukherjee et al., 2014a). While the NMR structures of these 
ICLs have not been determined, structural simulation studies estimate the conformations 
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to range from completely non-distorting (8-atom NM linker) to moderately distorting (5-
atom NM linker) (Mukherjee et al., 2014a; Roy and Schärer, 2016).  
Importantly, all crosslinker drugs generate a wide array of DNA adducts including 
monoadducts, intrastrand crosslinks (primarily between purines on the same strand of 
DNA), as well as ICLs. For example, MMC forms ICL lesions with about 15% 
efficiency. The rest are monoadducts (50%) and intrastrand crosslinks (35%). The 
efficiency for ICL formation for cisplatin is even lower, with less than 5% of lesions 
being ICLs.  
For this reason, rationally designed crosslinker drugs have been more recently 
synthesized in an effort to increase the efficiency of ICL formation. One such drug is 
SJG-136, a synthetic PBD (pyrrolo[2,1-c][1,4]benzodiazepine dimer). SJG-136 
preferentially reacts at purine-GATC-pyrimidine sequences, to form ICLs with high 
efficiency. The resulting SJG-136 ICL lesion forms in the minor groove of DNA and is 
minimally distorting (Martin et al., 2005; Rahman et al., 2009). Of note, while SJG-136 
forms ICLs at much higher efficiency than traditional crosslinker drugs, SJG-136 can 
also form stable intrastrand crosslinks and mono adducts (Rahman et al., 2009). 
 
Clinical Relevance of ICLs 
 
ICLs  are clinically relevant for two major reasons. First, DNA crosslinking agents 
are among the oldest and most widely prescribed anti-cancer drugs used today. They 
efficiently target rapidly dividing cancer cells by impeding the metabolic processes they 
need for cell homeostasis, growth, and proliferation, such as replication and transcription. 
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Second, the inability to repair ICL lesions is characteristic of a genome instability 
disorder called Fanconi Anemia. This suggests that endogenously occurring ICLs pose a 
threat to cells, and that their removal is essential for cellular homeostasis. Paradoxically, 
ICLs are therefore relevant for both the prevention and treatment of cancers.  
 
Crosslinker Drugs in Chemotherapy 
 
Crosslinker based chemotherapy began in 1946 with nitrogen mustard, which was 
followed by MMC in 1956, platinum based drugs in 1971, and psoralens in 1989. Today, 
these drugs are among the most effective therapies against various cancers including 
leukemia, lymphoma, colon, ovarian, bladder, testicular, head and neck cancers, to name 
a few. The clinical uses of the most common crosslinker drugs are summarized in Table 
1-3. 
There are key limitations in using crosslinker based chemotherapies. First, acquired 
resistance is a significant limitation of these drugs (Guainazzi & Schärer, 2010). Cancer 
cells can increase drug detoxification, reduce drug uptake, or evade crosslinker drug 
toxicity by accelerating DNA repair mechanisms or via overriding cell death pathways.  
For example, the clinical use of cisplatin is thought to be limited by cancer cells that 
upregulate DNA repair mechanisms. Overexpression of XPF-ERCC1, and some 
additional FA proteins have been observed in ovarian and testicular cancer cells that are 
exposed to cisplatin for long periods of time. Melanoma cells have been shown to acquire 
resistance to fotemustine (NM derivative) by upregulating XPC (Barckhausen, Roos, 
Naumann, & Kaina, 2014). 
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A second limitation of crosslinker drugs relate to dose limiting toxicity. Systemic 
delivery of the drugs results in toxicity in non-target tissues. Cisplatin for example, has 
been shown to specifically affect the brain, and patients also suffer from hearing loss, 
neuropathies, and kidney damage (Cheung-Ong, Giaever, & Nislow, 2013). Moreover, 
patients who undergo crosslinker based chemotherapy regimens often develop acute 
myeloid leukemia (Deans & West, 2011). 
Better understanding how cells respond to and repair DNA in response to crosslinker 
drugs will lead to improvements in cancer drugs, or lead to the development of 
combination therapies to help reduce drug toxicity and incidence of recurrence.  
 
Fanconi Anemia  
 
In humans, the inability to repair ICL lesions is associated with a genetic disorder 
called Fanconi Anemia (FA). FA is a rare disease, with an incidence rate estimated to be 
~1 in 100,000 to 400,000. FA was first described by Guido Fanconi in 1927, and today 
we now know that FA is caused by mutation in at least 21 “FANC” genes (name 
alphabetically from FANCA to FANCT). Among these, FANCA (65%) is the most 
commonly mutated gene, followed by FANCC (15%), and FANCG (10%) (D’Andrea & 
Grompe, 2003; Deans & West, 2011; Walden & Deans, 2014).  
FA is inherited in an autosomal-recessive fashion. The only except is FANCB which 
is X-linked. Clinical manifestations of FA patients are strikingly heterogeneous and 
include congenital abnormalities (microcephaly, short stature, genital and skeletal 
malformations), bone marrow failure, and cancer predisposition. Moreover, some patients 
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have only subtle or none of these phenotypes. Most FA patients, however, eventually 
develop bone marrow failure, which aids in the diagnosis of FA. FA is a genome 
instability disorder, and hence cancer, especially acute myeloid leukemia and squamous 
cell carcinoma of the head and neck, is also common among patients who undergo 
successful bone marrow transplants (Walden and Deans, 2014). 
Despite the clinical heterogeneity of FA patients, FA cells are all characterized by 
hypersensitivity to crosslinking drugs such as cisplatin, MMC, or diepoxybutane. Upon 
exposure to crosslinker drugs, FA cells characteristically arrest in G2/S phase, exhibit 
increased genome instability as assessed by chromosomal breakage tests, and die rapidly 
as measured by clonogenic survival assays (Kitao & Takata, 2011; Oostra, Nieuwint, 
Joenje, & de Winter, 2012). These analyses have been used as diagnostic markers for FA 
patients, helping clinicians identify the now 21 genes associated with FA disease.  
The extraordinary sensitivity of FA cells to crosslinker drugs, and not usually other 
DNA damaging agents such as hydroxyurea, UV, topoisomerase poisons was 
instrumental in identifying the role of FA proteins to the repair of ICLs. It is now well 
appreciated that FA proteins act in a common molecular pathway to repair ICL lesions. 
We have learned a lot about the molecular function of each of these FA proteins, not only 
in crosslink repair, but also as key players in other genome maintenance mechanisms 
including replication fork restart and stem cell maintenance (Ceccaldi, Sarangi, & 




Experimental Systems to Study ICL Repair 
 
Earliest investigations into ICL repair were done in bacteria and yeast. Genetic 
studies studying the sensitivity of cells to crosslinker chemicals helped identify the 
diverse DNA repair pathways that participate in ICL repair (Lehoczký et al., 2007; 
McVey, 2010).  
However, a limitation to inferring ICL repair capacity from drug sensitivity is that 
cellular responses to crosslinker drugs are complex. A single crosslinker drug can induce 
multiple types of lesions (monoadducts, intrastrand crosslinks, and a minority of ICLs), 
each eliciting multiple repair pathways. This collectively determines the sensitivity or 
resistance of a drug to cells. The mechanism by which specific proteins contribute to ICL 
repair cannot be discerned from these studies alone.  
Another limitation of these studies is that vertebrate ICL repair is more complex than 
bacteria or yeast. Indeed, the FA proteins, which play a central role in vertebrate ICL 
repair are completely absent in bacteria and not well conserved in yeast (McVey, 2010). 
Therefore FA-dependent ICL repair is fundamentally disparate between vertebrates and 
lower eukaryotes or prokarytoic organisms. Many studies therefore have utilized 
mammalian cell lines to study ICL repair. Specifically, cells from FA patients or other 
human cell lines, deficient of FA genes, have also been studied extensively. 
In addition to clonogenicity assays, ICL repair in cells has also been studied using 
reporter reactivation assays with site specific and structurally homogenous ICLs. In these 
experiments, ICL repair was monitored using GFP reporter in which GFP signal is only 
detected upon repair of the ICL lesion (Enoiu et al., 2012a; Williams et al., 2012). UV 
laser-induced psoralen ICLs have also been studied using immunofluorescence 
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(Muniandy et al., 2009a). Lastly, the recruitment of DNA repair proteins to ICLs can be 
monitored in mammalian cells using an episomal replication-based assay called eChIP 
(episomal chromatin immunoprecipitation) (Shen et al., 2009; Wang and Li, 2011).  
At least 11 FA mouse models have been generated (Bakker et al., 2013). While cells 
derived from these mice display sensitivity to crosslinker chemicals, the animals 
themselves, do not present with the developmental defects associated with FA and also 
do not spontaneously develop bone marrow failure. Yet, information gleaned from FA 
mouse models have still been tremendously important. For example, FA-deficient mice 
(FANCD2-/- Aldh2-/-) have been used to show how FA proteins function to protect the 
genome from damage caused by endogenous aldehydes (Garaycoechea et al., 2012; 
Langevin et al., 2011; Oberbeck et al., 2014; Pontel et al., 2015).  
Biochemical studies using purified proteins and model ICL substrates have been 
particularly important in determining the molecular mechanism for ICL repair. These 
studies have provided insight into several catalytic steps in the repair process including 
incision and trimming events (Klein Douwel et al., 2017; Klein Douwel et al., 2014; 
Sarkar et al., 2006). Moreover, studying the repair of structurally defined ICL substrates 
have proved important, since the repair of ICL lesions can be influenced by its structure 
(Hlavin et al., 2010a).  
All of the aforementioned experimental approaches are suitable for studying ICL 
repair that occurs in the context of replication. However, some of these approaches can 
also be adapted to study repair that occurs outside S-phase. For example, cells in culture 
are rapidly dividing and hence primarily undergo replication coupled ICL repair 
mechanisms, and the contribution of replication-independent mechanisms can be 
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diminished or lost in cells, unless cells are arrested and studied in G0/G1 phase. This is 
true of clonogenic survival assays, or immunofluorescence-based psoralen ICL repair 
studies. Similarly, ICL repair in plasmid-based experiments can be done on non-
replicating plasmids. Nevertheless, a key limitation is that studies in G0/G1 arrested cells 
or non-replicating plasmids cannot precisely discriminate between transcription-initiated 
repair and sensor-mediated ICL repair mechanisms. Xenopus laevis cell-free extracts, 
described in detail below, has emerged as a particularly useful model system to study 
sensor-mediated ICL repair.  
 
Xenopus laevis Cell-Free Extracts 
 
The African clawed frog, Xenopus laevis, cell-free extracts have provided a unique 
and powerful system to elucidate and dissect multiple molecular mechanisms of ICL 
repair (Ben-Yehoyada et al., 2009; Klein Douwel et al., 2014, 2014). Adult female frogs 
can be stimulated to lay hundreds of unfertilized eggs by injection with human chorionic 
gonadotropin. These eggs are arrested at metaphase of Meiosis II collected and used to 
prepare cell free extracts through a series of centrifugation steps. These cell-free extracts 
can be prepared as a replication competent low-speed supernatant (LSS) to study 
replication coupled ICL repair mechanisms, or prepared as a high-speed supernatant 
(HSS), which is not competent for replication and is also transcriptionally silent. The 
latter type of extract is therefore particularly useful to study sensor mediated replication 
independent ICL repair processes (Figure 1-6).  
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Remarkably, Xenopus extracts contain all DNA repair machinery, allowing the 
extracts to fully recapitulate mammalian DNA replication and repair processes including 
BER, NER, MMR, and DSBR. The mechanism of these pathways can be carefully 
dissected using this biochemically amenable system. Essential proteins can be 
specifically and quantitatively depleted from extracts without resulting in lethality. 
Moreover, the extracts can also be supplemented with recombinant proteins, peptides, or 
drugs.  
Xenopus extracts are DNA-free, and therefore exogenous DNA substrates including 
chromatin or plasmids can be introduced to the extract to study DNA dynamics and repair 
mechanisms. Upon incubation in Xenopus extracts, the DNA bind histone proteins and 
assemble into nucleosomes (Lemaitre et al., 2001). This allows endogenous repair 
proteins to physically interact and repair the ICL lesion in a highly physiological 
environment. Using this system, ICL repair has been studied both within the context of 
sperm chromatin (Raschle et al., 2015) and also plasmid based systems (Ben-Yehoyada et 
al., 2009; Kato et al., 2017; Räschle et al., 2008; Williams et al., 2012).  
The advantage of using a plasmid based system is that a single, structurally defined 
ICL lesion can be monitored in the absence of any other type of DNA damage (Ben-
Yehoyada et al., 2009; Räschle et al., 2008; Williams et al., 2012). Purifying the ICL 
plasmid from extract during repair and processing and analyzing the proteins that are 
associated with the substrate can be monitored by ChIP or plasmid pull-down 
experiments. Additionally, the repair of the ICL site can be monitored either by radio-
nucleotide incorporation, or by quantitative PCR.  
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Insights into ICL repair, both in and out of the context of the context of replication, 
gleaned from work using the Xenopus extract system is described in detail in the 
following sections.  
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ICL Repair Mechanisms 
 
If unrepaired or inappropriately repaired, ICL lesions can lead to genome instability 
and cell death. It has been estimated that a single unrepaired ICL lesion in bacteria or 
yeast, and 20-40 ICLs in human cells could result in cell death (McVey, 2010; Muniandy 
et al., 2010). It is therefore critical for cells to be able to efficiently sense and repair ICL 
lesions.  
Yet, repairing an ICL lesion is a formidable task for cells; ICLs are an intrinsically 
complex type of DNA damage as they span both strands of the double helix. And this 
complexity is reflected in ICL repair processes, which harnesses repair proteins from 
multiple distinct DNA repair pathways (Raschle et al., 2015). These include BER, NER, 
MMR, TLS (Roy and Schärer, 2016), and HR. Moreover, multiple mechanisms for ICL 
repair have been described, and the manner in which ICLs are repaired is dependent on 
cell-cycle, and can also be influenced by ICL structure (Roy et al., 2016; Semlow et al., 
2016). 
Most modalities of ICL repair involve several common processing steps including (1) 
ICL recognition (2) ICL “unhooking” where dual incision flanking the ICL are made by 
structure specific endonucleases (3) ICL processing in which the unhooked lesion is 
enzymatically trimmed by an exonuclease, and (4) lesion bypass and repair synthesis. 
However, depending on the type of ICL repair, the proteins responsible for each of these 
steps vary. Furthermore, recently an incision-independent ICL mechanism has been 
described, in which ICLs are processed in a far simpler reaction as will be discussed in 
detail below.  
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ICL repair mechanisms can be separated into two broad categories, based on the 
manner in which cells recognize the ICL lesion. Repair that is tightly coupled to 
replication is termed: “replication coupled repair” (RCR) that is strictly restricted to S-
phase of the cell cycle, and repair that occurs independently of replication is called: 
“replication-independent repair” (RIR) and occurs predominantly in G1/G0/G2-phases of 
the cell cycle (Figure 1-4). 
 
Replication Coupled Repair 
 
In rapidly proliferating cells, the most efficient modality of ICL repair operates 
during S-phase (Figure 1-5). During replication, the CMG helicase (Cdc45-MCM-GINS) 
complex unwinds the DNA helix ahead of the active replisome. Progression of replisome 
is physically blocked when the CMG helicases encounter an ICL lesion, triggering repair 
of the ICL (Räschle et al., 2008). In Xenopus extracts, the collision of two replication 
forks are required, suggesting that an X-shaped DNA structure is required for ICL repair 
(Zhang et al., 2015). An alternative model for ICL repair in which a single collision event 
is required to initiate repair has also been reported in mammalian cells (Huang et al., 
2013; Rohleder et al., 2016) 
Following this ICL recognition step, the ICL can be processed in two mechanistically 
different ways. The first requires a complex repair reaction involving the Fanconi 
Anemia proteins (Ben-Yehoyada et al., 2009; Klein Douwel et al., 2014; Knipscheer et 
al., 2009; Long et al., 2011) and the NER proteins. A DSB repair intermediate is 
generated, which is repaired by the homologous recombination (HR) machinery. An 
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alternative mechanism of repair is catalyzed by the BER enzyme, NEIL3 glycosylase 
(Semlow et al., 2016). In this modality of ICL repair, DSBs are not generated, and ICL 
repair proceeds with the direct cleavage of the ICL lesion, followed by repair synthesis 
by TLS polymerases. The repair mechanisms specific to each pathway, and 
considerations pertaining to pathway choice is discussed below.    
 
Fanconi Anemia Dependent ICL Repair Pathway 
The mechanism of FA dependent replication coupled ICL repair pathway has been 
deciphered using Xenopus extracts and replicating plasmids containing a single defined 
ICL lesion. Together with genetic and biochemical studies, a detailed model for FA-
dependent ICL repair has emerged (Figure 1-5, right). In this model, 21 FA proteins, 
together with proteins from the HR, NER, and TLS pathways cooperate to accomplish 
repair of ICL lesions (Walden and Deans, 2014).  
The first step in ICL repair upon recognition of the lesion by the replication 
machinery, is the ubiquitin –mediated unloading of the CMG helicases by the 
BRCA1(FANCS)-BARD1 complex (Long et al., 2014). This allows the replisomes, 
which are initially stalled at the -20 positions on the leading strands to approach the ICL 
to the -1 position on either side of the offending adduct. Importantly, in Xenopus extracts, 
the convergence of two forks are required to activate ICL repair, suggesting that an X-
shaped replication intermediate triggers ICL repair during S-phase (Zhang et al., 2015). 
Interestingly, Rad51(FANCR) localizes to sites of stalled forks at these early timepoint in 
RCR, well before DSB formation (Long et al., 2011). It is possible that Rad51 operates to 
prevent fork breakage/degradation during this time.  
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Upon stalling of the replication fork at ICL lesions, the FA pathway is activated. And 
the FA core complex, comprised of 14 proteins: FANCA, FANCB, FANCC, FANCE, 
FANCF, FANCG, FANCL, and FANCM as well as FAAP20, FAAP24, and FAAP100 
and MHF1 and MHF2 associate with the damaged chromatin. This complex functions as 
an E3 ubiquitin ligase and catalyzes the ubiquitination of the FAND2-FANCI 
heterodimer, a hallmark event in FA pathway activation.  
Ubiquitylated FANCD2-FANCI complex is recruited to the ICL lesion, and promotes 
the unhooking of the ICL lesion by recruiting the SLX4 (FANCP) scaffold, as well as the 
XPF(FANCQ)-ERCC1 endonuclease (Klein Douwel et al., 2017; Klein Douwel et al., 
2014). It remains unclear if XPF-ERCC1 alone is responsible for the unhooking of the 
ICL lesion. There have been reports that the CtIP is recruited by the FANCD2-FANCI 
complex to further promoting FA and HR-dependent ICL repair (Murina et al., 2014; 
Unno et al., 2014).  
A direct result of the unhooking of an ICL adduct during replication is the formation 
of a DSB in one of the sister chromosomes. This is repaired by a final group of FA 
proteins BRCA1 (FANCS), BRIP1 (FANCJ), PALB2 (FANCN), BRCA2 (FANCD1), 
RAD51C (FANCO), and RAD51 (FANCR), which together with the rest of the HR 
machinery repairs the DSB using HR.  
Unhooking also produces a sister chromatid with an unhooked ICL adduct that 
requires further steps for repair. First, the crosslink adduct which remain covalently 
attached to one end of the DNA is thought to be nucleolytically trimmed by the 
exonuclease SNM1A (Wang et al., 2011). Nucleolytic degradation of the unhooked ICL 
decreases its size, and helps facilitate downstream repair reactions including repair 
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synthesis. In replication coupled repair, the Pol ζ (Rev3-Rev7 heterodimer) and Rev1 
contribute to bypass synthesis.  
Of note, an alternative model for ICL repair has been proposed by the Seidman group, 
in mammalian cells using UV-psoralen ICL adducts and DNA combing (Huang et al., 
2013; Rohleder et al., 2016). In this mechanism of ICL repair, a single fork that 
encounters an ICL lesion, is able to bypass the lesion. ICL repair only occurs after the 
replication machinery has traversed the offending adduct. Although it remains unclear 
how ICL traverse could occur, one theory is FANCM functions to push CMG helicases 
past ICL lesions during this process. These results strongly suggest that an X shaped 
DNA substrate is the critical signal to trigger ICL repair, as opposed to the double 
collision model that has been proposed by the Walter lab.  
 
NEIL3 Dependent ICL Repair Pathway 
A second mechanism of replication coupled ICL repair has been elucidated using 
Xenopus extracts and psoralen- and Ap-ICLs (Figure 1-5, left). In this modality of repair, 
collision of CMG helicase is followed by a ICL cleavage by the NEIL3 glycosylase 
(Semlow et al., 2016). Interestingly, NEIL3 is a bifunctional glycoslyase, meaning it can 
hydrolyze glycosydic bonds, as well as catalyze a lyase reaction to create a single strand 
break in the DNA backbone. However, during repair of Ap-ICL lesions, NEIL3 only 
contributes a single incision to release the ICL, a reaction that leaves behind an abasic 
site (Ap site) on one strand, and an intact thymine nucleotide on the other. The abasic 
lesion is mutagenically bypassed by a TLS polymerase, completing the ICL repair 
process, and allowing replication to proceed. Of note, Ap-ICL lesions are repaired 
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predominantly using NEIL3-dependent mechanism (80%), but can also be repaired in the 
FA-dependent pathway.  
In Xenopus extracts, the repair of Ap-ICL lesions, which occurs preferentially by 
NEIL3, is repaired significantly better (40%) compared to FA-dependent repair of 
cisplatin ICLs (15-20%). Together these studies reveal that while ICL sensing by the 
replication machinery allows for structurally distinct ICLs to be recognized to similar 
degrees, pathway choice and repair efficiency are heavily influenced by the chemical 
identity of the ICL. Further, in order for ICLs to be processed in the glycosylase-
dependent manner, the ICL lesion must be amenable to cleavage by enzymes such as 
NEIL3.  
 
Replication Independent Repair 
 
ICLs repair that occurs outside of S-phase is termed replication independent repair 
(RIR). RIR is critical for homeostasis and survival in cells that are slowly- or non-
dividing (for example, neurons), or in cells deficient for replication coupled repair 
proteins (i.e. Fanconi anemia cells) (Hlavin et al., 2010a; Muniandy et al., 2009b; Shen et 
al., 2006). RIR may also be a critical pathway in the context of tumorigenesis. 
Crosslinker-drugs efficiently target rapidly dividing cells by physically blocking DNA 
transactions including replication and/or transcription. Whereas, in slower-dividing cells 
which require less DNA transactions, ICL repair by RIR may be sufficient for cell 
survival, and may therefore facilitate drug resistance and cancer recurrence.  
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There are many lines of evidence in support of RIR. First, yeast in G1 phase undergo 
ICL repair (Sarkar et al., 2006). Similarly, G1 arrested mammalian cells process ICLs 
(Hlavin et al., 2010a; Muniandy et al., 2009b; Shen et al., 2006; Zheng et al., 2003). 
Moreover, ICLs are processed in non-replicating mammalian cell extracts (Smeaton et 
al., 2008, 2009), and ICLs are fully repaired in replication incompetent Xenopus extracts 
(Ben-Yehoyada et al., 2009; Kato et al., 2017; Williams et al., 2012). 
RIR is mechanistically distinct from ICL repair that occurs during replication in 
several key ways. First, ICLs recognition must occur independent of replication-
associated DNA unwinding, the principle mechanism by which ICLs are identified by 
cells during replication. Second, ICL repair during RIR does not involve generation of a 
DSB intermediate, which is a hallmark of FA-dependent repair during S-phase. Indeed, 
Rad52 deficient yeast have wild-type sensitivity to ICL drugs when grow to stationary 
phase, suggesting that repair in G0/G1 phase does not involve homologous recombination 
(McHugh et al., 2000). Instead, RIR is thought to proceed with two rounds of an 
excision-repair mechanism reminiscent of BER, NER, and MMR (Cole, 1973). While 
presented mechanistically (Figure 1-7), this model for RIR is largely based on genetic 
studies in bacteria and yeast. Aside from PCNA and Pol κ, which have been identified as 
two essential RIR factors (Williams et al., 2012), the identity and function of most other 
RIR proteins remain elusive.  
RIR has been particularly challenging to elucidate for several reasons. First, ICL 
repair has been primarily studied in yeast and mammalian cells. Cells in culture are 
highly proliferative, and therefore biased towards replication-dependent repair and 
against RIR. Another complication in studying RIR is due to the variety of ICL substrates 
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investigators use to study RIR. Structurally distinct ICL lesions can be recognized and 
processed with different efficiency and mechanistically divergent ways by cells, a level 
of complexity that is absent during replication coupled repair, where all ICLs, regardless 
of structure, will block the replication machinery. 
Nevertheless, there is evidence that NER (Thoma et al., 2005; Wood, 2010) and 
MMR (Kato et al., 2017; Zhao et al., 2009) proteins help process ICLs during RIR 
(Hlavin et al., 2010b; Noll et al., 2006; Williams et al., 2013). In fact, eCHIP based 
protein-recruitment studies even suggest that select FA proteins may play a role in RIR 
(Shen et al., 2009). However, how these proteins contribute to the productive repair of 
ICLs during RIR remains controversial. This idea will be discussed in detail below. 
 
Transcription Initiated ICL Repair Pathway 
Analogous to the stalled replication machinery triggering ICL repair, there is 
evidence that stalled transcription machinery can elicit repair of ICL lesions. ICLs placed 
in actively transcribed regions are processed more efficiently than ICLs in non-
transcribed regions (Islas et al., 1991). Moreover, ICLs in constitutively transcribing 
plasmids (that do not replicate because they lack mammalian origins of replication) are 
repaired in mammalian cells, and processed preferentially on the transcribed strand 
(Zheng et al., 2003). 
Not surprisingly, TC-NER proteins, specifically CSA and CSB, as well as GG-NER 
proteins are implicated in transcription initiated ICL repair. When placed downstream of 
a strongly active transcriptional promoter, the repair of NM- and BCNU-like ICLs are 
dependent on CSB, XPF, and XPG, as well as the Rev 1 and Pol ζ polymerases (Hlavin et 
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al., 2010a). The repair of MMC-ICLs were dependent on CSA (Zheng et al., 2003). The 
repair of cisplatin ICLs have similarly been studied and required XPA, XPF, and XPG 
(Enoiu et al., 2012a). As anticipated for a transcription driven recognition process, the 
these ICLs were by and large not dependent on XPC (Enoiu et al., 2012a; Hlavin et al., 
2010a).  
Most of the work pertaining to transcription initiated ICL repair are performed on 
plasmid systems where the ICL is placed in between a constitutively active promoter and 
a reporter gene. While this system has been instrumental in identifying proteins that 
contribute to the processing of the ICL lesion, the system is inherently biased towards 
transcription-coupled repair, and provides limited insight into the mechanism of the 
repair process and how this might occur under physiological circumstances. 
Importantly, ICL repair efficiency during transcription-initiated repair can be 
influenced by ICL structure. Miller et al. found that synthetic analogs of NM-ICLs were 
repaired with >5 fold efficiency than two analogs of BCNU-ICLs (Hlavin et al., 2010a). 
 
Sensor Mediated ICL Repair Pathway 
ICLs can occur in DNA that is neither replicating or undergoing transcription (Ben-
Yehoyada et al., 2009; Williams et al., 2012). In the absence of collision with polymerase 
complexes, ICLs must be recognized and funneled into a repair pathway by DNA damage 
sensors that surveil the genome for aberrant DNA structures. ICLs can result in 
destabilization of base stacking in its vicinity, and this distortion can assist in damage 
recognition. DNA damage sensors from the NER and MMR pathways are strong 
candidates to participate in this role. 
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Global-genome nucleotide excision repair sensor, XPC, has been implicated by 
several studies in ICL repair (Wood, 2010). XPC-Rad23B associates with TFO-
conjugated psoralen ICL adducts in vitro (Thoma et al., 2005). Plasmids harboring a 
single TFO-psoralen ICL are also bound by XPC in vivo. XPC also localizes to laser 
induced psoralen ICL lesions in G1 arrested cells (Muniandy et al., 2009b), and the 
recruitment of XPC to psoralen-UV damaged nuclei was important for the disappearance 
of psoralen-UV ICLs. Furthermore, a plasmid-based reporter experiment also showed 
that XPC is partially required for the repair of MMC ICLs in cells (Zheng et al., 2003). 
The role of XPC in the repair of cisplatin ICL lesions is harder to interpret. XPC 
deficient cells do not show marked sensitivity for crosslinker drugs (Enoiu et al., 2012a; 
Wood, 2010). This is often contrasted to the acute sensitivity of XPF-ERCC1 deficient 
cells to crosslinker drugs (Wang et al., 2011; Wood, 2010). The repair of plasmids (bulk) 
treated with psoralen or cisplatin have been studied in host reactivation assays, where 
XPC does contribute to DNA repair (Chen, 2003). However, these results are difficult to 
interpret since in vitro studies with a cisplatin oligonucleotide showed that XPC and other 
NER proteins preferentially process intrastrand crosslinks, and not ICLs (Zamble et al., 
1996).  
The difference in requirement for XPC in these studies could be explained by the 
ability of XPC to favor recognition of ICLs of specific structure and chemistry. Psoralen 
and MMC ICLs which are less distorting may be more amenable to recognition by XPC 
than cisplatin ICLs, which are severely distorting.  
Alternative candidates to recognize ICLs in the absence of replication and 
transcription are the mismatch repair sensors, MutSa (MSH2-MSH6) and MutSb 
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(MSH2-MSH3). Like XPC, the MutS proteins are versatile DNA damage recognition 
factors. MuSα binds recognizes O6-methylguanine, O4-methylthymine, or the cisplatin-D 
(GpG) intrastrand crosslinks in vitro, as measured by electromobility shift assays 
(EMSA) (Duckett et al., 1996; Yamada et al., 1997), and psoralen (Vasquez, 2010) and 
cisplatin ICL. Similarly, MutSb binds psoralen ICLs (EMSA) in vitro (Zhang et al., 
2002).  
Recently, an unbias proteomics approach was used to study the recruitment of DDR 
proteins to psoralen treated chromatin using  Xenopus extracts (Raschle et al., 2015). In 
this study, the authors report that MSH2 and MSH6 are enriched on damaged chromatin, 
and that this occurred in a replication independent manner. This suggests that MutSa 
may play a role in ICL repair both during and outside of S-phase (Raschle et al., 2015). 
Indeed, MSH2 and MSH6 deficient mammalian cells show defects in FA pathway 
activation, as assessed by FANCI-FANCD2 ubiquitination in response to psoralen and 
MMC treatment (Huang et al., 2011; Williams et al., 2011). And in non-replicating 
Xenopus extracts MutSa is not only bind to multiple ICL types, but is also required for 
the efficient repair of trimethylene ICLs through recruitment of the MMR machinery 
(Kato et al., 2017). Finally, there is also some evidence in yeast that MutS proteins are 
important during S-phase repair of nitrogen mustard induced damage (bulk treatment) 
(Barber et al., 2005a).  
There is also genetic evidence for the MutS proteins in ICL repair. However, the 
results are confounding. Loss of MutSa has been associated to MMC sensitivity 
(Fiumicino et al., 2000; Huang et al., 2011; Jung and Lippard, 2007; Peng et al., 2014; 
Williams et al., 2011), as well as oxaliplatin (Jung and Lippard, 2007), CDDP (Williams 
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et al., 2011), and NMs (Fiumicino et al., 2000). In contrast, MutSa deficiency has also 
been extensively linked to cisplatin-resistance: reviewed in (Jung and Lippard, 2007). 
Finally, several other studies also find that MMR deficient cells have no phenotype when 
treated with crosslinker drugs (Enoiu et al., 2012a; Hlavin et al., 2010a).  
At least two major factors account for these discrepancies. First, clonogenic survival 
assays measure the combined impact of loss of a protein on the diverse types of DNA 
damage that are generate by crosslinker drugs (mostly monoadducts or intrastrand 
crosslinks), only a minority of which are ICLs. Clonogenic survival assay, especially in 
asynchronous cells, is not an optimal system to study sensitivity specific to ICLs. 
Investigators also use a variety of cell types, the majority of which are cancer cells. These 
cells sometimes have widely variable karyotypes and hence may respond to crosslinker 
drugs in unique ways.  
Furthermore, cells may respond to structurally distinct ICLs in different ways 
(Kothandapani et al., 2011, 2013). This is especially true regarding cisplatin ICLs, for 
which there is extensive literature associating cellular resistance of MSH2 deficient cells 
to cisplatin (Kothandapani et al., 2011, 2013; Sawant et al., 2015; Yamada et al., 1997).  
Taken together, inferring the contribution of DNA repair proteins from crosslinker 
sensitivity studies alone are not sufficient to deduce the roles of these proteins in ICL 
repair. Instead, careful biochemical studies using defined ICL substrates are needed to 
better understand ICL repair, especially RIR. Moreover, ICL repair mechanisms must be 
defined in the context of structure, the context of DNA in which the damage occurs, 
transcriptional status of the DNA, as well as the cell cycle.  
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There is abundant additional evidence that ICL structure and its chemical properties 
affect how ICLs are processed by cells. In mammalian cell extracts (HeLa and CHO 
cells) which are replication and transcriptionally silent, the efficiency of ICL unhooking 
and reprocessing on a 150 base pair linear DNA (blocked on either end with biotin 
moieties to prevent degradation) is dependent on ICL structure (Smeaton et al., 2008, 
2009).  
ICL structure may further influence repair kinetics because the repair intermediates 
may vary in structure. For example, upon recognition, ICLs are unhooked on one side of 
the DNA by enzymatic incision events. The length of duplex DNA surrounding an 
unhooked ICL lesion may therefore vary depending on (1) the distance from the ICL 
lesion at which the endonucleolytic incisions occur to unhook the ICL, and (2) the degree 
of exonucleolytic resection that occurs following unhooking of the ICL (Roy and 
Schärer, 2016; Roy et al., 2016). By shortening the duplex region, resection is thought to 
reduce the need for strand displacement synthesis during repair synthesis by translesion 
synthesis polymerases (Roy et al., 2016). The SNM1A (Wang et al., 2011) and FAN1 
(Pizzolato et al., 2015; Wang et al., 2014) nucleases can process DNA duplexes 
containing ICLs, while the EXO1 exonuclease cannot (Kato et al., 2017). However, these 
nucleases are primarily thought to function in replication coupled ICL repair pathway. 
Finally, the efficiency of repair synthesis may vary between different ICLs. Indeed, more 
distorting (5-atom linker) NM ICL lesions facilitate strand displacement and approach to 
the ICL lesion, while less distorting (8-atom linker) NM ICLs are extended more 
efficiently after insertion (Roy et al., 2016). 
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While the proteins responsible for ICL recognition during RIR has been challenging 
to determine, PCNA and translesion synthesis polymerase Pol κ have been identified to 
be two essential RIR factors in the repair of trimethylene-ICL lesions (Williams et al., 
2012). Williams et al., showed using Xenopus cell-free extracts that ICL repair during 
RIR, monoubiquitinated PCNA recruits Pol κ to sites of ICL repair to accomplish repair 
synthesis. Because PCNA ubiquitination is a hallmark of polymerase switching, 
additional polymerases are thought to participate during various stages of repair 
synthesis: (1) approach (2) insertion of a nucleotide across the unhooked lesion, and (3) 





Chapter 1 Tables 
 
Table 1-1 DNA Lesions generated by endogenous and exogenous sources 
 
Endogenous sources of DNA Damage DNA Lesions Generated 
Estimated Number 
Lesions / Cell / 
Day 
Spontaneous depurination or 
ribonucleotide incorporation Ap site 10000 
Cytosine deamination Base transition 100-500 
7meG 7meG 4000 
O6meG O6meG 41576 
Oxidation 8oxoG 400-1500 
Reactive aldehydes or rearrangement of 
AP site Interstrand crosslinks 10
a 
Exogenous sources of DNA Damage 
(dose exposure in mSV) DNA Lesions Generated 
Estimated Number 
Lesions / Cell 
Peak hr sunlight (NA) 
Cyclobutane-pyrimidine 
dimers (CPDs) and 6-4 
pyryimidine prymidone 
photoproducts (6-4PPs) 
100,000 / day 
Cigarette smoke (NA) Aromatic DNA adducts 45 - 1029 
Chest X-rays (0.02) DSBs 0.00 
Dental X-rays (0.01) DSBs 0.00 
Mammography (0.40) DSBs 0.02 
Body CT (0.01) DSBs 0.28 
Head CT (2.00) DSBs 0.08 
Airline travel (0.005/hr) DSBs 0.0002/hr 
Space mission (60 days; 50.00) DSBs 2.00 
Hiroshima and Nagasaki atomic bombs 
(765670.00) DSBs 0.2-160 
Table is adapted from (Ciccia and Elledge, 2010) 























   
 
N/A 
PDB 1BNA 1A2E N/A 204D NA 
Source (Drew et al., 1981) 







(Johnson et al., 
2013)  
 






Preference 5’–GC 5’–CG 5’–purine-GATC-pyrimidine 5’–GAC 
ICL 
structure 
   
 
PDB 1LUH 2KNK N/A N/A 
Source (Dooley et al., 2003)   
(Dooley et 



























Table 1-3 Crosslinker drugs used in the clinic 
 
Drug 
Class Drug Name Clinical Application 
Platinums 
Cisplatin Bladder, ovarian, testicular cancer 
Carboplatin Ovarian cancer 
Oxaliplatin Colorectal cancer, colon cancer 




Leukemia, lymphoma, multiple 
myeloma, neuroblastoma, 
retinoblastoma, ovarian and breast 
cancer 
Melphalan Multiple myeloma, ovarian caner 
Chlorambucil Chronic lymphocytic leukemia, lymphoma 
Ifosfamide Testicular cancer 
   
Other 
Mitomycin C Pancreatic adenocarcinoma and gastric cancer 
Psoralen Cutaneous T cell lymphoma 
Pyrrolobenzodiadiazepines Phase II trial for solid tumors 
Table is adapted from (Deans and West, 2011). Clinical application is based on National 











Figure 1-1. Sources and types of DNA Damage 
DNA damage can occur through endogenous and exogenous sources. Many classes of 
DNA damage exist, including simple base lesions such as abasic sites, bulky adducts, or 
mispaired DNA bases. More complex lesions include DNA double strand breaks, 





















Figure 1-2. DNA repair pathways for Base Excision Repair, Nucleotide Excision 
Repair, and Mismatch Repair 
Base excision repair (BER) removes DNA bases that have been damaged. BER is 
initiated by lesion-specific DNA glycosylases. Either a single base (short patch BER) or a 
few bases (long patch BER) are removed, before the site is repaired by a translesion 
synthesis polymerase. Nucleotide excision repair (NER) fixes bulkier adducts. NER is 
initiated by XPC-HR23B, which senses distortions in the DNA helix. Incisions are made 
surrounding the damaged lesion, and the short oligonucleotide containing the damage site 
is removed. The resulting ~30 base gap is filled in by translesion synthesis polymersases. 
NER can also be initiated by the transcription machinery (not illustrated). Mismatch 
repair (MMR) is initiated by one of two mismatch repair sensor MutSa or MutSβ. The 
region containing the mispaired base is excised, and the resynthesis reaction is typically 






base damage bulky adduct



















Figure 1-3. DNA repair pathways of Double Strand Break Repair 
Double strand breaks can be repaired either through Non-homologous end joining 
(NHEJ) or by homologous recombination (HR). NHEJ occurs robustly throughout the 
cell cycle and involves the direct ligation of broken ends. In contrast, HR only occurs in 
late S or G2 phases of the cell cycle when a homologous sister chromatid is available and 
able to serve as a template for repair. During HR, DNA ends are resected extensively, and 





















Figure 1-4. Pathways of ICL repair 
ICLs can be recognized and repaired by multiple, mechanistically-distinct pathways. A 
defining feature of each pathway lies in the manner in which the ICL is recognized and 
repaired. In replication coupled repair, the ICL is recognized by the DNA replication 
machinery, which scans the entire genome during S-phase. ICLs can also be funneled 
into a repair pathway by the transcription machinery that may also collide with a 
damaged site, or by DNA damage sensor proteins that sense distortions in the DNA and 
activate repair. These include the XPC and MutSa MutSb proteins from th NER and 





















Figure 1-5. Pathways of Replication Coupled ICL repair 
Replication coupled ICL repair is activated when replisomes collide with an ICL during 
replication. If the ICL lesions is amenable to cleavage by the NEIL3 glycosylase, they 
undergo direct cleavage. The resulting abasic site (red dot) is then repaired by the BER 
machinery. Some ICLs are not processed by NEIL3, and instead are funneled into a 
Fanconi Anemia dependent pathway. In this alternative mechanism, 21 FA proteins 
cooperate to accomplish ICL repair. In this process, incision events result in the 
FANCG
CMG unloading, and 












CMG progression blocked by ICL 
























































generation of a DSB intermediate, and therefore the homologous recombination 




Figure 1-6. Schematic of preparation of Xenopus cell-free extracts (High Speed 
Supernatant) 
Unfertilized eggs from adult female frogs are used to prepare Xenopus cell-free extracts. 
Through a series of centrifugation steps, the eggs are crushed and a membrane and DNA-
free extract is prepared. This extract, which is named “High Speed Supernatant” is 
replication incompetent and transcriptionally silent. HSS contains all cytosolic proteins 
required for DNA repair mechanisms including NER, MMR, and DSBR. HSS also 
support the repair of ICL lesions.   
HSS












Figure 1-7. Conceptual model of Replication Independent ICL Repair 
ICL lesions can be recognized by DNA damage sensor proteins that sense distortions in 
DNA. Two incision events occur flanking the damaged lesion. The unhooked ICL lesion, 
which remains tethered to the DNA on one strand, undergoes trimming. This makes room 
for the repair synthesis step which requires PCNA and at least one TLS polymerase, Pol 
κ. There is growing evidence for MMR and NER proteins to function both in the sensing 
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• ICLs are sensed and repaired independently of replication and transcription 
• MutSa (MSH2-MSH6) binds to ICLs and initiates repair 
• ICL structure influences recognition and repair efficiency 




Kato et al. identify a mechanism of ICL recognition that operates independently of DNA 
replication and transcription. In the absence of these processes, ICLs are recognized and 
repaired by the MMR machinery. MutSa is critical for ICL recognition, while MutLa 






DNA interstrand crosslinks (ICLs) that are repaired in non-dividing cells must be 
recognized independently of replication-associated DNA unwinding. Using cell-free 
extracts from Xenopus eggs that support neither replication nor transcription, we establish 
that ICLs are recognized and processed by the mismatch repair (MMR) machinery. We 
find that ICL repair requires MutSa (MSH2-MSH6) and the mismatch recognition FXE 
motif in MSH6, strongly suggesting that MutSa functions as an ICL sensor. MutSa 
recruits MutLa and EXO1 to ICL lesions, and the catalytic activity of both these 
nucleases is essential for ICL repair. As anticipated for a DNA unwinding-independent 
recognition process, we demonstrate that least distorting ICLs fail to be recognized and 
repaired by the MMR machinery. This establishes that ICL structure is a critical 





DNA interstrand cross-links (ICLs) are lesions that covalently link opposing strands 
of the double helix. ICLs physically block cellular processes that require the unwinding 
of the DNA molecule, such as replication, recombination, and transcription. ICLs can 
also interfere with essential protein-DNA binding events such as transcription factor 
binding. Chemicals that induce ICLs, such as nitrogen mustards, platinum drugs, and 
mitomycin C are therefore extremely cytotoxic, and are routinely used in the clinic as 
anti-cancer chemotherapies (Deans and West, 2011). Importantly, ICLs also arise as a 
consequence of cellular metabolism, for instance through production of reactive 
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aldehydes such as malondialdehyde, acetaldehyde, and formaldehyde (Duxin and Walter, 
2015) or by chemical rearrangements at abasic DNA sites (Price et al., 2014). 
ICLs vary greatly in structure and the degree to which they distort DNA. These structural 
differences can influence the manner in which cells process the ICLs. Indeed, in yeast, 
the repair pathway that responds to crosslinking damage differs according to the 
crosslinking drug (Beljanski et al., 2004). In mammalian cells, the efficiency of ICL 
unhooking and repair is greater for a distorting ICL than for a non-distorting ICL (Hlavin 
et al., 2010a; Smeaton et al., 2008). Furthermore, at least two replication coupled ICL 
repair mechanisms have been described in Xenopus extracts for which the primary 
determinant of repair pathway choice is based on ICL structure (Semlow et al., 2016). 
In proliferating cells, most repair occurs during S-phase, when ICL sensing is a 
direct consequence of replication. Active replisomes stall at ICLs and trigger a complex 
reaction that requires the Fanconi Anemia (FA) proteins (Ben-Yehoyada et al., 2009; 
Klein Douwel et al., 2014; Knipscheer et al., 2009; Räschle et al., 2008) or the NEIL3 
glycosylase (Semlow et al., 2016). Non-dividing yeast cells grown to stationary phase 
(Sarkar et al., 2006) and G1-arrested mammalian cells (Hlavin et al., 2010a; Muniandy et 
al., 2009b; Shen et al., 2006), harness an alternative modality of repair termed 
Replication Independent Repair (RIR) (Williams et al., 2012). To date, the molecular 
components that contribute to RIR have not been fully defined. A fundamental question 
that remains unanswered is how ICLs are recognized without replisome/ICL clashes. 
Collision between the transcription machinery and ICLs could activate repair. Indeed 
ICLs are more efficiently processed when placed in transcribed regions (Islas et al., 
1991), and repair of ICLs placed in constitutively transcribing plasmids show dependence 
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for transcription-coupled and global-genome nucleotide excision repair proteins (Enoiu et 
al., 2012a). However, RIR is initiated in Xenopus extracts in the absence of both 
replication and transcription (Ben-Yehoyada et al., 2009; Williams et al., 2012), 
suggesting ICLs can be directly funneled into a repair pathway by DNA damage sensor 
proteins. But no ICL sensor has yet been unambiguously identified, and it is not clear 
how structurally distinct ICL lesions are recognized and/or subsequently repaired during 
RIR. 
The mismatch repair (MMR) pathway is a highly conserved DNA repair mechanism 
that primarily functions to correct replication errors that escape proofreading. MMR is 
initiated by the MutSa complex (MSH2-MSH6 heterodimer) which recognizes and binds 
single base mismatches and 1-2 base insertion/deletion loops. Binding of MutSa to 
mispaired bases leads to the recruitment of downstream DNA repair proteins including 
the MutLa endonuclease (MLH1-PMS2 heterodimer), RPA, EXO1, and PCNA. 
Together, these proteins catalyze an excision-repair reaction to restore proper Watson-
Crick base-pairing, and can effectively increase the fidelity of replication by up to three 
orders of magnitude. In humans, mutations in either subunit of MutSa (MSH2 and 
MSH6) account for 50-60% of germline mutation-based (Lynch Syndrome) and 15-20% 
of sporadic colorectal cancers (Reyes et al., 2015). 
Importantly, MutSa has multiple roles outside of replication. MutSa is active in 
quiescent (post-mitotic) mammalian cells, such as terminally differentiated neurons, 
where the complex participates in genome maintenance mechanisms by recognizing not 
only canonical DNA mismatches, but also responding to chemically modified DNA bases 
(Iyama and Wilson, 2013; Schroering et al., 2007). For example, plasmids containing 
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single O6-methyl-guanine adducts (O6meG) are processed in a MutSa-dependent fashion 
in non-replicating mammalian (York and Modrich, 2006) and Xenopus extracts (Olivera 
Harris et al., 2015), although leading sometimes to futile repair cycles (Fu et al., 2012). In 
addition to O6meG, MutSa specifically recognizes bulky lesions such as O4-
methylthymine adducts and cisplatin intrastrand crosslinks in vitro. Crystal structures of 
human MutSa bound to these DNA substrates reveal a common mechanism of damage 
recognition that requires an N-terminal FXE motif found in the MSH6 subunit (Warren et 
al., 2007). Binding of MutSa to DNA lesions leads to a variety of cellular outcomes 
including repair, checkpoint activation, and apoptosis, underscoring the versatile and 
critical role that MutSa plays in genome maintenance. 
In this study, we demonstrate a role for the MMR machinery in ICL repair. Using 
non-replicating and transcriptionally-silent Xenopus extracts, we show that MutSa binds 
to plasmids bearing a single site-specific ICL and harnesses the entire MMR machinery, 
including the MutLa and EXO1 nucleases, to perform ICL repair. We also compare the 
repair of structurally-different ICLs, including two analogs of the malondialdehyde ICL 
and a nitrogen mustard-like ICL (Guainazzi et al., 2010). We conclude that ICL structure 





MutSa (MSH2-MSH6) senses DNA interstrand crosslinks 
The MutSa complex recognizes a diverse array of aberrant DNA structures including 
base-base mispairs and chemically modified DNA adducts. We hypothesized that the 
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ability of MutSa to recognize distortions within DNA might also extend to interstrand 
crosslinks (ICLs), and that sensing of ICLs by MutSa could initiate ICL repair by a set of 
reactions analogous to MMR. To test this hypothesis, we first asked whether MutSa 
binds preferentially to ICLs in non-replicating Xenopus extracts (High Speed Supernatant 
- HSS) using a plasmid pull-down assay. Notably, these cell-free extracts support ICL 
repair and restore the integrity of both DNA strands (Williams et al., 2012). 
We used SJG-136, a rationally designed crosslinking drug, to generate plasmids with 
a single site-specific ICL lesion. SJG-136 preferentially forms ICLs between guanine 
residues at 5’-purine-GATC-pyrimidine-3’ sequences (Figure S2-1A) (Gregson et al., 
2001). We treated oligonucleotide duplexes containing a single SJG-136 reaction site 
(Figure S2-1B), and purified crosslinked duplexes by denaturing PAGE. These oligos 
were ligated into a small plasmid (pBS: pBlueScript), and further purified by cesium 
chloride density ultracentrifugation. 
Following incubation in HSS, we isolated plasmid and plasmid-bound proteins from 
the extract using biotinylated lac repressor protein and streptavidin beads, as previously 
described (Williams et al., 2012). Western blot analysis revealed that the crosslinked 
plasmid was enriched in bound MSH2 and MSH6 when compared to identical 
undamaged control plasmids (Figure 2-1A). 
In order to study the dose-dependent response of MutSa to crosslinks, we conducted 
a similar experiment with plasmids containing multiple ICLs by treating double-stranded 
pBS plasmids in vitro with increasing doses of SJG-136 (Figure S2-1C-E). We observed 
dose-dependent increase of MSH2 and MSH6 binding to damaged plasmids (Figure 2-
1B), after normalizing for plasmid recovery using qPCR (Figure S2-1F). We also observe 
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the recruitment of PCNA and RPA to these plasmids in a dose-dependent manner, 
suggesting that the cross-linked plasmids were undergoing processing and repair. 
Consistent with the accumulation of RPA and with our previous studies (Ben-Yehoyada 
et al., 2009; Williams et al., 2012), incubation of the SJG-136-treated plasmids in HSS 
triggered phosphorylation of cytosolic Chk1 (Figure S2-1G), a marker for ATR 
checkpoint activation. 
Next, we asked whether MutSa is required for ICL repair. ICL plasmids harboring a 
single, site-specific trimethylene ICL lesion (5’GpC-ICL), for which an NMR structure 
has been described were used as substrates (Protein Data Bank: 2KNL) (Dooley et al., 
2003). In contrast to the temperature-sensitive ICLs generated by SJG-136, the 
trimethylene crosslink is extremely stable at high temperature. We can therefore monitor 
ICL repair by quantitative PCR by comparing the increase in amplification of the 
damaged “X” region to that of an undamaged “C” region on the plasmid backbone over 
time (Ben-Yehoyada et al., 2009; Williams et al., 2012) (Figure S2-1B, right). 
Incubation of cytosol with MSH2 antibodies raised against Xenopus MSH2 protein 
depleted both MSH2 and MSH6 subunits of MutSa (Figure 2-1C, left), but did not 
reduce the cytosolic levels of other MMR proteins including MLH1 and EXO1 (Figure 2-
1C, right). Compared to mock-depleted extracts, depletion of MutSa significantly 
decreased ICL repair (Figure 2-1D). Importantly, addition of recombinant MutSaWT to 
MSH2-depleted extracts restored ICL repair to the level of mock-depleted extracts. 
Moreover, over-expression of MutSaWT in undepleted HSS increased the ICL repair 
efficiency (Figure 2-1E), suggesting that lesion recognition by MutSa is a rate-limiting 
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step during RIR. These data establish that MutSa is required for ICL repair in the 
absence of DNA replication and transcription. 
Mechanism of ICL recognition by MutSa 
MutSa discriminates aberrant DNA substrates amid a vast excess of normal DNA 
bases. The MSH6 subunit contributes critically to this process in at least two ways. First, 
the MSH6 subunit contains a highly conserved FXE motif (Figure S2-2A,B) that 
functions during damage recognition (Lamers et al., 2000; Malkov et al., 1997): the 
aromatic ring of the phenylalanine residue stacks with the mispaired base, whereas the 
carboxyl group of the glutamic acid residue hydrogen bonds with the mispaired base 
(Warren et al., 2007). A single amino acid substitution of this phenylalanine residue 
prevents efficient recognition of mispaired bases in yeast (Bowers et al., 1999), and 
results in defective repair in human cell extracts (Dufner et al., 2000). 
To test the possible role of the FXE motif in MutSa-dependent repair of ICL in 
Xenopus extracts, we cloned and purified Xenopus mismatch binding-deficient MutSaFXE 
complex (Figure S2-2A,B,D). First, we asked if the F411A substitution affected 
mismatch repair using a plasmid-based MMR assay in HSS extracts. We used plasmids 
containing a single A:C mismatch and a 15 nucleotide gap on the 3’ side of the A-strand 
(pMM1AC) to trigger gap-directed strand-specific MMR (Figure 2-2A), as previously 
described (Kawasoe et al., 2016). Repair of this plasmid occurs preferentially on the A-
strand, and the correction of the A:C site to a G:C pair generates a BamHI restriction site 
(Figure 2-2A, top). Background levels of repair on the C-strand is monitored by digestion 
with XhoI (Figure 2-2A, bottom). 60 minutes after incubation in mock-depleted extracts, 
37% of the A:C mismatches were repaired to G:C. As anticipated, MMR was abolished 
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in MSH2-depleted extracts. Addition of recombinant MutSaWT, but not MutSaFXE 
restored repair (Figure 2-2A, top). The requirement for the FXE motif for MMR is 
therefore conserved in Xenopus. 
Next, we determined if the F411A substitution ablated ICL repair. As shown in 
Figure 2-2B, recombinant MutSaFXE was unable to support repair of ICLs in MSH2-
depleted extracts. The FXE domain is, therefore, critical for ICL damage recognition. 
In addition to recognizing a mismatched base, MSH6 also interacts with proliferating 
cell nuclear antigen (PCNA). Studies using fluorescently-tagged proteins show that the 
interaction between MSH6 and PCNA is important for the colocalization of the MutSa 
complex to replication factories in S. cerevisiae (Hombauer et al., 2011) and in human 
cells undergoing MMR (Kleczkowska et al., 2001). Yet, disruption of the PCNA-MSH6 
interface results in a modest MMR phenotype (Shell et al., 2007), and other PCNA-
independent recruitment of MutSa to mismatches via histone methylation has also been 
described (Li et al., 2013). 
We used plasmid pull-down assays to ask whether MutSa was recruited to ICLs in a 
PCNA-independent manner. As shown in Figure 2-1B, the MutSa complex and PCNA 
were recruited to SJG-treated plasmids in HSS extracts. MutSa recruitment was not 
dependent on PCNA; MSH2 and MSH6 were efficiently recruited to crosslinked 
plasmids in PCNA-depleted extracts. Furthermore, the extent of MutSa recruitment was 
unaffected by supplementation of extracts with recombinant PCNA protein (Figure 2-
2C). This experiment strongly suggests that MutSa can be recruited to ICLs 
independently of PCNA. 
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The interaction between MSH6 and PCNA is mediated by a PCNA interaction motif 
(PIP box) in MSH6 (Clark et al., 2000; Flores-Rozas et al., 2000). We constructed 
recombinant MutSa complex with a triple amino acid substitution in its conserved PIP 
box motif: Q(X)2LI(X)2FF (Figure S2-2A,C,D) that disrupts PCNA interaction with 
MutSa in vitro (Figure S2-2G). We tested the ability of this MutSaPIP to support ICL 
repair in MutSa-depleted extracts. We find that MutSaPIP is unable to support ICL repair 
(Figure 2-2B). This indicates that whereas MSH6-PCNA interaction is not required for 
MutSa recruitment to ICLs, and presumably for ICL sensing, the interaction between the 
two is essential for coordinating downstream repair events. 
 
ICLs are processed by MutLa and EXO1 nucleases 
The earliest catalytic events during ICL repair are thought to be dual endonucleolytic 
incisions flanking the ICL lesion in a process referred to as “unhooking”. However, 
neither the exact mechanism nor the nuclease(s) involved in the process are known for 
RIR. 
We engineered the ICL-containing plasmids with 4 unique nicking sites flanking the 
ICL (Figure 2-3A and Figure S2-3A). We hypothesized that presenting the extract with a 
pre-nicked plasmid might stimulate ICL repair if the substrate resembled a 
physiologically relevant ICL repair intermediate. Indeed, introduction of a single nick 19 
base pairs (bp) 5’ to the ICL lesion stimulated repair by 4-fold. In contrast, nicks 15 bp or 
30 bp 3’ to the ICL or 34 bp 5’ to the ICL failed to stimulate repair (Figure 2-3B). We 
conclude that incision 5’ to the ICL is a rate-limiting step during the repair process. It 
further suggests that a 5’ incision close to the ICL (19 bp vs. 34 bp), is optimal for repair 
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and could reflect the physiological site of incision. Finally, the asymmetry between 3’ 
and 5’ incisions could reflect the action of 2 distinct nucleases. 
Our evidence that MutSa is recruited to ICLs and is required for their repair 
prompted us to investigate the possible role of the mismatch-associated MutLa (MLH1-
PMS2 heterodimer) endonuclease in ICL repair. Recruitment of MutLa to SJG-136 
treated plasmids was observed following incubation of SJG-136-treated plasmid in 
extracts (Figure 2-3C). Notably, MLH1 recruitment was critically dependent upon 
MutSa, since MLH1 binding to the ICL-containing plasmid was abrogated in MSH2-
depleted extracts (Figure 2-3C). 
Specific antibodies against Xenopus MLH1 quantitatively depleted both MLH1 and 
PMS2 from extracts (Figure 2-3D, left). Importantly, MLH1 depletion did not affect the 
levels of MSH2 and MSH6 in the cytosol (Figure 2-3D, right), and MSH2 and MSH6 
were still enriched on SJG-136 treated plasmids in MLH1-depleted extracts (Figure S2-
3E, left). Removal of MLH1/PMS2 reduced ICL repair by 50%, and addition of 
recombinant MutLaWT to MLH1-depleted extract restored repair (Figure 2-3E). 
Therefore, MutLa is not only recruited by MutSa to ICL plasmids, it is also necessary 
for efficient ICL repair. 
The PMS2 subunit of MutLa complex contains a conserved endonuclease motif 
DQHA(X)2E(X)4E. Substitution of E707 to K abolishes the endonucleolytic activity 
associated with PMS2 and yields a strong mutator phenotype in S. cerevisiae (Smith et 
al., 2013). Mutation of the corresponding residue (PMS2-E702K) in mice increases 
genomic mutation rates and cancer predisposition (van Oers et al., 2010). We generated 
the equivalent mutation in Xenopus MutLa (MLH1-PMS2E674K) (Figure S2-3B-D). 
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Recombinant MutLa lacking endonuclease activity did not support ICL repair in 
MLH1-depleted extract (Figure 2-3E). Furthermore, overexpression of nuclease deficient 
MutLa complex significantly reduced ICL repair, possibly by acting as a dominant-
negative (Figure 2-3F). Overexpression of recombinant MutLa complexes did not 
interfere with MutSa recruitment to SJG-136 treated plasmids (Figure S2-3E, right). 
These results indicate that PMS2-associated nuclease activity is required for ICL repair. 
The dual incision flanking the ICL lesion during “unhooking” produces an 
oligonucleotide that remains covalently attached to DNA by the ICL adduct and is base-
paired on each side of the ICL. During replication coupled ICL repair, this DNA 
fragment is degraded with 5’à 3’ polarity by the SNM1A exonuclease, presumably 
allowing DNA polymerases to be loaded (Wang et al., 2011), and for other downstream 
repair reactions to take place. 
We speculated that the 5’à 3’ EXO1 exonuclease could fulfill a similar function in 
RIR. In an in vitro reconstituted vertebrate MMR system, EXO1 degrades the single-
strand oligonucleotide harboring the mismatch (Genschel et al., 2002). We found that 
EXO1 was recruited to SJG-136 treated plasmids. As is the case for MutLa, EXO1 
recruitment was dependent on MutSa: EXO1 binding to the ICL-containing plasmid was 
reduced in MSH2-depleted extracts (Figure 2-4A). A specific antibody generated against 
Xenopus EXO1 quantitatively depleted EXO1 from extracts (Figure 2-4B). ICL repair 
was significantly reduced in EXO1-depleted HSS. This defect could be rescued by 
addition of EXO1WT, but not catalytically inactive EXO1D173A (Figure 2-4C) (Liao et al., 
2011). This demonstrates that EXO1 and its nuclease activity are required for ICL repair 
in the absence of DNA replication and transcription. 
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To evaluate the specific contribution of EXO1 during ICL repair, we conducted in 
vitro nuclease assays (Wang et al., 2011). First, we purified the catalytic domain of 
human EXO1 (EXO1352) from E. coli as previously described (Shi et al., 2017). EXO1352 
harbors robust nuclease activity in vitro, but lacks its C-terminal region (Figure S2-4A), 
important for making connections with various protein binding partners including MSH2, 
MLH1, PCNA, and RPA (Shi et al., 2017). 
Duplex oligonucleotides containing a single SJG-136 ICL lesion are easily 
distinguished by size from uncrosslinked duplex on a denaturing polyacrylamide gel 
(Figure S2-4B). Similarly, the reaction products upon incubation with EXO1352 can be 
visualized and identified. We generated control duplex DNA with only one free 5’ end 
available for processing (the 5’ end of the other strand blocked by addition of a biotin 
moiety). This template is efficiently processed by EXO1352 from the biotin-free 5’ end in 
the 5’ to 3’ direction as anticipated (Figure 2-4D, left). Exonucleolytic processing was 
abolished when both ends of the duplex are blocked with biotin, confirming that under 
these experimental conditions, only the exonuclease activity contributes to the processing 
of the DNA substrates. When EXO1352 was incubated with similar ds-DNA 
oligonucleotides containing a single SJG-136 ICL lesion, EXO1352 was able to initiate 
processing of the substrate from an available 5’ end. However, EXO1 processing was 
blocked by the ICL lesion (Figure 2-4D, right). EXO1352 is therefore unable to bypass an 
ICL under these conditions. 
Incubation of plasmids harboring ICL lesions activates the RPA-ATR-pChk1 branch 
of the DNA damage response (Figure S2-1G). Next, we assessed the role of replication 
protein A (RPA) in ICL repair. Trimeric RPA protein complex was depleted using an 
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antibody generated against RPA1. Depletion of RPA from HSS extracts completely 
abolished ICL repair. ICL repair was restored by addition of recombinant Xenopus 
trimeric RPA complex (Figure S2-4C-E). This is consistent with our previous studies in 
which we reported a requirement for RPA in ICL repair in LSS extracts (Low Speed 
Supernatant) treated with geminin and roscovitine to inhibit replication (Ben-Yehoyada et 
al., 2009). 
We predicted that RPA binding to crosslinked plasmids during ICL repair would 
occur primarily after ICL recognition and initiation of ICL unhooking events. We found 
that MSH2, MSH6, and MLH1 were loaded to similar levels to SJG-136 treated plasmids 
following incubation in mock- and RPA-depleted extracts (Figure S2-4F). This result 
supports a model in which MutSa and MutLa play early roles during ICL repair, 
preceding nucleolytic events during the repair. 
 
The efficiency of RIR is influenced by ICL structure 
In replicating extracts, ICLs are sensed by a translocating replisome that stalls at the 
ICL. In RIR, we suggest ICL sensing is dependent on distortion of the DNA helix at the 
lesion. To test this idea, we compared the kinetics of repair between chemically related 
trimethylene ICLs in two distinct structural conformations: the more distorting 5’-GpC-
ICL (Dooley et al., 2003) and the less distorting 5’-CpG-ICL (Dooley et al., 2001) 
(Figure 2-5A and Figure S2-5A). Both ICLs were ligated into a pEGFP vector backbone 
(Figure S2-5B). We found that the more distorting ICL induced a stronger ATR 
checkpoint activation (Figure 2-5B). Furthermore, repair of the more distorting lesion 
was 40% more efficient than the less distorting lesion (Figure 2-5C). We next asked 
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whether repair of these ICLs was dependent upon MutSa. As shown in Figure 2-5D, 
repair of both trimethylene crosslinks displayed a similar requirement for MSH2. Thus, 
MutSa is able to recognize structurally distinct ICL lesions. 
Finally, we monitored repair of a chemically distinct nitrogen mustard-like ICL lesion 
(Figure 2-5E and Figure S2-5A). This NM-ICL is generated within the major groove with 
minimal distortion of the DNA helix, allowing the DNA to maintain B-DNA 
conformation (Guainazzi et al., 2010; Mukherjee et al., 2014b). Interestingly, even after 3 
hours of incubation there was no detectable repair of this NM-ICL (Figure 2-5E). This 
supports our notion that ICL recognition in RIR depends on DNA distortion, and is 
consistent with a previous report that repair of NM-ICLs are entirely dependent on 




MutSa is a bona fide ICL sensor 
The mechanism(s) by which ICLs are sensed and repaired in non-dividing cells has 
been difficult to elucidate. In this study, we used Xenopus HSS extracts, which do not 
replicate or transcribe, to identify eukaryotic mismatch repair complex, MutSa (MSH2-
MSH6), as a sensor of ICL lesions. Our conclusion is supported by the following 
observations. First, MutSa was recruited to plasmids containing ICL lesions (Figure 2-
1A,B). Second, MutSa carrying its mismatch binding FXE motif was required for repair 
of trimethylene ICLs (Figure 2-2B). Third, binding of MutSa to ICL was required for 
recruitment of downstream repair proteins including MutLa (Figure 2-3C) and EXO1 
(Figure 2-4A). 
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We conclude that binding of MutSa to ICLs precedes nucleolytic processing, and 
thus acts at an early step in ICL repair. Moreover, overexpression of MutSa in extracts 
enhanced ICL repair efficiency (Figure 2-1E), further suggesting MutSa senses ICLs, 
and that such sensing is a rate-limiting step in repair. 
We observe that MutSa-dependent ICL repair has slower kinetics than the repair of 
mismatches in Xenopus extracts (Kawasoe et al., 2016; Radman, 2016). We surmise that 
the complexity of the ICL lesion, which requires two rounds of repair synthesis during 
RIR, could account for this difference. 
Importantly, we find that structurally distinct ICLs were repaired with varying 
efficiencies. Trimethylene-ICLs, which significantly distort DNA were repaired with 
robust efficiency, in contrast to non-distorting NM-like ICLs, which had no detectible 
repair (Figure 2-5C,E). This indicates that ICL repair by RIR is critically dependent on 
ability of the ICL lesion to be recognized by DNA damage sensor proteins. Thus, repair 
of ICLs in G0/G1 utilizes a fundamentally different mechanism than ICL repair during S-
phase, when lesion sensing occurs by replisomes stalled at ICLs irrespective of crosslink 
structure. Moreover, ICL recognition by MutSa during RIR may also be influenced by 
sequence context, as has been proposed for MMR (Mazurek et al., 2009). 
Of note, MutSa (MSH2-MSH6) is one of two mismatch repair sensors that operate 
during MMR in vertebrates. The other is MutSb (MSH2-MSH3), which is about 10 times 
less abundant than MutSa in mammalian cells and has higher specificity for recognizing 
larger insertion-deletion loops (IDLs) and branched DNA substrates (Genschel et al., 
1998). Depletion of MSH2 from extracts quantitatively depleted MSH6 and MSH3. Our 
depletion-rescue experiments with recombinant MutSa, which fully rescues ICL repair, 
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helps assign the specificity of ICL recognition to MutSa (Figure 2-1D). In mammalian 
cells, MutSb along with the global genome nucleotide excision repair sensor, XPC 
(xeroderma pigmentosum complementation group C) have been linked to psoralen ICL 
repair (Muniandy et al., 2009b; Thoma et al., 2005; Zhang et al., 2002; Zhao et al., 2009). 
However, how these complexes contribute to the repair of ICLs remains unclear. 
We were unable to detect direct binding of MutSa to SJG-136 treated 
oligonucleotides using EMSA experiments. This could be due to the design of the oligo 
duplex itself, which is restricted in length (~20 bases) to ensure SJG-136 generates a 
single ICL and to avoid the formation of secondary structures, since the duplex must be 
almost exclusively be composed of A and T nucleotides. While our data using the 
mismatch binding deficient (FXE) mutant MutSa (Figure 2-2B) strongly suggest that 
MutSa binding to DNA is critical for ICL repair, we cannot formally rule out that 
additional proteins participate in recruiting MutSa to ICLs. 
 
The role of PCNA during Replication Independent Repair 
Previously we reported that PCNA is an essential RIR factor. We showed that PCNA 
ubiquitinylated at lysine (K164) is required to recruit Polk to ICL sites for repair 
synthesis (Williams et al., 2012). The experiments described here indicate that PCNA is 
not essential for MutSa recruitment to ICLs (Figure 2-2C). However, we find a 
requirement for interaction between MutSa and PCNA for ICL repair (Figure 2-2B). This 
suggests that PCNA may help retain MutSa at damage sites, or perhaps enhance 
MutSa’s damage recognition specificity, as has been suggested during MMR (Clark et 
al., 2000; Flores-Rozas et al., 2000; Kleczkowska et al., 2001). Our data show that PCNA 
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plays an upstream role during ICL repair, in addition to supporting Polk recruitment for 
repair synthesis. 
We also probed the requirement for binding between PCNA and components of the 
MMR machinery by generating mutations in the interdomain connector loop (IDCL) of 
PCNA. Mutations in this region abrogate interactions with MSH6 and PMS2 in vitro, and 
cause MMR defects in yeast (Lee and Alani, 2006). We made the equivalent mutations in 
Xenopus PCNAL126A,I128A  (Figure S2-2E,F). However, we were not able to determine the 
contribution of the PCNA:MutSa interface to ICL repair using the this mutant, since 
binding between MutSaWT and PCNAL126A,I128A was enhanced, as measured by co-
immunoprecipitation, compared to binding between MutSaWT and PCNAWT (Figure S2-
2G). Accordingly, both PCNAWT and PCNAL126A,I128A were able to rescue ICL repair 
defects in PCNA-depleted extracts (Figure S2-2H,I). 
 
Insights into nucleolytic processing of ICLs by MutLa and EXO1 
Following sensing, an ICL is thought to be processed in two consecutive nucleolytic 
steps. First, dual incisions surrounding the ICL are made to produce an “unhooked” 
oligonucleotide, which is covalently tethered to the DNA by the ICL adduct. The 
unhooked lesion is then resected in a “trimming” reaction that facilitates synthesis past 
the adduct by translesion synthesis polymerases by eliminating the need for displacement 
synthesis (Roy et al., 2016). In replication coupled ICL repair the XPF-ERCC1 
endonuclease and SLX4 promote unhooking of ICLs (Klein Douwel et al., 2014), and the 
SNM1A exonuclease has been proposed to process unhooked ICL lesions (Wang et al., 
2011).  
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We investigated the role of these nucleolytic reactions in RIR. We used nicked 
plasmids to identify that a 5’ incision 19 base pairs away from an ICL lesion was able to 
stimulate repair by 4-fold. This is in contrast to nicks placed 15 bp or 30 bp 3’ to the ICL 
or 34 bp 5’ to the ICL, all of which failed to stimulate repair (Figure 2-3B). This 
experiment demonstrates a striking mechanistic difference between RIR and MMR. 
MMR is stimulated symmetrically by either a 5’ or a 3’ nick in vitro (Constantin, 2005; 
Varlet et al., 1996). Our results also suggest that 5’ incision is a rate-limiting step during 
RIR, and that 2 distinct nucleases are required during ICL repair. Depletion-rescue 
experiments with MutLa strongly suggest that MutLa promotes one or both of these 
incisions. However, because it is generally thought that MutLa requires a pre-existing 
nick and interaction with PCNA to stimulate its otherwise latent endonuclease activity, it 
is possible that another, as yet unidentified nuclease, is responsible for the initial incision. 
Our discovery that MutSa and MutLa participate in ICL repair highlights the versatile 
roles DNA repair proteins play in genome maintenance. This idea is further exemplified 
by our finding that EXO1 is required during RIR. EXO1 is a 5’à 3’ exonuclease that is 
not only involved in MMR, but also plays critical roles in double-strand break repair and 
telomere maintenance (Tran et al., 2004). In all of these roles, EXO1 catalyzes digestion 
of DNA by hydrolyzing phosphodiester bonds between adjoining normal nucleotides. 
The requirement for EXO1’s nuclease activity during ICL repair (Figure 2-4C) suggests 
that EXO1 could process complex, chemically modified DNA substrates, including 
crosslinked bases. However, our in vitro experiments in which EXO1352 was unable to 
bypass an ICL lesion strongly suggests that EXO1 alone cannot efficiently process ICLs 
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(Figure 2-4D). However, it is conceivable that ICL processing by EXO1 requires 
association with other proteins through its C-terminus.  
During replication coupled ICL repair, SNM1A has been proposed to operate 
similarly to EXO1 in processing unhooked ICL lesions (Wang et al., 2011). In addition, 
there is evidence that the FAN1 nuclease can digest past ICL-containing oligonucleotides 
in vitro (Pizzolato et al., 2015; Wang et al., 2014). However, we find that FAN1 
depletion in Xenopus HSS extracts has no effect on ICL repair (unpublished data). 
 
Conclusions  
DNA crosslinking agents are among the most widely prescribed anti-cancer drugs 
used in the clinic. Yet, acquired resistance remains is a significant limitation of these 
drugs (Deans and West, 2011). It seems likely that alterations to pathways that contribute 
to the repair of ICLs, the principle cytotoxic lesion generated by these drugs, may 
underlie acquired resistance. It is therefore critical to fully understand how cells respond 
to and repair ICLs.  
We provide compelling evidence that the MMR pathway contributes to ICL repair. 
This is in agreement with a recent study that used an unbiased proteomic approach to 
study protein recruitment to psoralen-ICLs using quantitative mass spectrometry. This 
study revealed that MSH2, MSH6, PMS2, and EXO1 associate with cross-linked 
chromatin (Raschle et al., 2015). Importantly, recruitment of these proteins was resistant 
to geminin, suggesting that MMR proteins may play a role in ICL repair both in and 
beyond G0/G1 phase. Indeed, requirement for MSH2 and EXO1 has been reported in 
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repair of nitrogen mustard ICLs in S-phase yeast (Barber et al., 2005b), and in S-phase 
mammalian cells defective in the Fanconi Anemia pathway (Huang et al., 2011).  
In this study, we provide mechanistic insights into how MMR proteins cooperate to 
accomplish ICL repair (Figure 2-6). We propose that ICLs that are recognized by MutSa 
are processed by MutLa and EXO1 in an incision-excision reaction, followed by DNA 
synthesis process that requires PCNA and Polk. Further, our work stresses the importance 
of distinguishing between structurally distinct ICLs, which may be repaired in 
overlapping and/or divergent ways. Future experiments should address whether the 




Xenopus cell-free extract and depletions 
Xenopus laevis frogs were handled in accordance with guidelines provided by the 
Institutional Animal Care and Use Committee at Columbia University, protocol 
AAAK0551. For details regarding the preparation of cell-free extracts and depleted 
extracts see Supplemental Experimental Procedures. 
 
Preparation ICL plasmids 
SJG-136 treated plasmids were prepared by incubating pBS with indicated concentrations 
of SJG-136 (NCI/Spriogen LTD) in 50 mM triethanolamine and 2 mM EDTA, overnight 
at 37°C. Plasmids were ethanol precipitated and resuspended in water. The quality and 
quantity of plasmids recovered were analyzed by agarose gel electrophoresis with 
ethidium bromide, Nanodrop measurement, and qPCR. The amount of plasmid used in 
plasmid pull-down experiments was normalized accordingly. The preparation of plasmids 
containing a single SJG-136, trimethylene, or NM-like ICL lesion is described in detail in 
Supplemental Experimental Procedures. 
 
ICL repair and lac repressor plasmid pull-down experiments in Xenopus extracts 
Lac repressor plasmid pull-down assays in un-depleted and depleted HSS extracts were 
performed as described previously (Williams et al., 2012). ICL repair assays in HSS were 
performed essentially as describe previously (Ben-Yehoyada et al., 2009; Williams et al., 
2012). Each of these assays, as well as the MMR assay of a site-specific A:C mispair is 
described in detail in Supplemental Experimental Procedures. 
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Statistical Analysis 
All statistical analyses were performed using GraphPad Prism 7 software using paired 
Student’s T-test or ANOVA. Data annotated as ns=p>0.05; (*)=p≤0.05; (**)=p≤0.01; 
(***)=p≤0.001 
 
Protein Expression and Purification 
Recombinant MutSa, MutLa, RPA, PCNA, and EXO1 were purified as described in 
Supplemental Experimental Procedures. 
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Chapter 2 Figures 
 
 
Figure 2-1. ICL sensing by MutSa (MSH2-MSH6) 
(A) Plasmid pull-down assay of control plasmids or plasmids containing a single site-
specific SJG-136 ICL lesion. Plasmids were incubated for 40 min in HSS then 
purified from extracts using recombinant Bio-LacR protein coupled to streptavidin 
beads. Plasmid-bound proteins were analyzed by Western blot (WB) using the 
indicated antibodies. 
(B) Plasmid pull-down assay and WB of SJG-136 treated plasmids. In the last lane, 
labeled (10x2), twice the amount of 10 µM treated plasmids was incubated in HSS. 
Input are plasmid DNA run on an agarose gel. 
(C) MSH2-MSH6 immunodepletion. Mock- and MSH2-depleted HSS were analyzed by 
WB. 
(D) Quantification of ICL repair in Mock- and MSH2-depleted HSS at 3 hrs. Results 
represent mean ± SEM from n=7 independent experiments. 
(E) Quantification of ICL repair in HSS and HSS supplemented with MutSaWT at 3 hrs. 
Results represent mean ± SEM from n=11 independent experiments. 
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Figure 2-2. Mechanism of ICL recognition by MutSa (MSH2-MSH6) 
(A) Plasmids containing a single site-specific A:C mismatch were incubated in Mock-, 
MSH2-depleted, or MSH2-depleted HSS supplemented with recombinant MutSaWT 
or MutSaFXE for the indicated amount of time. Mismatch repair efficiency was 
measured by digestion with XmnI with BamHI or XhoI restriction enzymes, for 
AàG repair (top) and CàT repair (bottom), respectively. Data is representative of 
three independent experiments. 
(B) Quantification of ICL repair in Mock-, MSH2-depleted, or MSH2-depleted HSS 
supplemented with recombinant MutSaWT [n=7], MutSaFXE [n=6], or MutSaPIP [n=4] 
at 3 hrs. Results represent mean ± SEM of independent experiments. 
(C) Plasmid pull-down assay and WB of SJG-136 treated plasmids in Mock- or PCNA-
depleted extract. 
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Figure 2-3. Nucleolytic incision of ICL lesions by MutLa (MLH1-PMS2) 
(A) Schematic of nicking sites engineered into ICL pBS plasmids (See also Figure S3A). 
(B) Quantification of ICL repair in HSS of un-nicked, 5’ or 3’ nicked plasmids at 90 min. 
Results represent mean ± SEM from n=6 independent experiments. 
(C) Plasmid pull-down assay and WB of SJG-136 treated plasmids in Mock- or MSH2-
depleted extract. 
(D) MLH1-PMS2 immunodepletion. Mock- and MLH1-depleted HSS was analyzed by 
WB. 
(E) Quantification of ICL repair in Mock-, MLH1-depleted, or MLH1-depleted HSS 
supplemented with recombinant MutLaWT [n=12] or MutLan.d [n=7] at 90 min. 
Results represent mean ± SEM independent experiments. 
(F) Quantification of ICL repair in HSS with overexpression of buffer, MutLaWT, or 
MutLan.d. at 90 min. Results represent mean ± SEM from n=5 independent 
experiments. 







































































































Figure 2-4. Nucleolytic processing of ICL lesions by EXO1 
(A) Plasmid pull-down assay and WB of SJG-136 treated plasmids in Mock- or MSH2-
depleted extract. 
(B) EXO1 immunodepletion. Mock- and EXO1-depleted HSS was analyzed by WB. 
(C) Quantification of ICL repair in Mock-, EXO1-depleted, or EXO1-depleted HSS 
supplemented with recombinant EXO1WT or EXO1D173A at 3 hrs. Results represent 
mean ± SEM from n=7 independent experiments. 
(D) Exo1352 nuclease assay with control or SJG-treated oligonucleotides. Reaction 
products were run on a denaturing polyacrylamide gel and stained with SYBR Gold. 





































































Figure 2-5. ICL structure and repair efficiency 
(A) Structures of normal B-form DNA (PDB: 1BNA), and DNA duplexes containing 
trimethylene 5’ GpC-ICL (PDB: 1LUH) and 5’ CpG-ICL (PDB: 2KNK) lesions. 
(B) Plasmids containing single trimethylene GpC or CpG-ICL were incubated in HSS, 
and soluble extracts were analyzed by WB. 
(C) Quantification of ICL repair of trimethylene GpC and CpG plasmids at the indicated 
time points. Results represent mean ± SEM from n=4 independent experiments. 
(D) Quantification of ICL repair of trimethylene GpC and CpG plasmids in Mock- and 
MSH2-depleted HSS at 3 hrs. Results represent mean ± SEM from n=4 independent 
experiments. 
(E) Quantification of ICL repair of trimethylene GpC and NM-like ICL plasmid using 
TaqMan qPCR reagent at the indicated time points. Results represent mean ± SEM 
from n=3 independent experiments. 










































































Figure 2-6. Model for MMR mediated ICL repair 
ICLs can be recognized and repaired in the absence of replication. MutSa complex 
senses and binds ICL lesions, and recruits downstream repair proteins including the 
MutLa endonuclease, PCNA, and EXO1 exonuclease. The ICL lesion is repaired through 
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Chapter 2 Supplemental Materials 
 
 
Figure S2-1. Schematic of ICL plasmids and preparation of SJG-136 treated 
plasmids 
(A) SJG-136 preferentially reacts with DNA at guanine residues at 5’ purine–GATC–
pyrimidine sequences to form ICLs. 
(B) Sequences of trimethylene and SJG-136 ICL oligos that were ligated into pBS to 
construct plasmids with a single site-specific ICL (left). Schematic of the resulting 
ICL plasmid. The binding site for Bio-LacR used for plasmid pull-down experiments, 
and primers used for qPCR to calculate ICL repair are illustrated (right). 
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(C) Schematic representation of pBS treated with SJG-136. The 7 sequences 
corresponding to SJG-136 ICL forming sites are illustrated. The single SJG-136 
reaction site that overlaps with a BamHI recognition sequence is specified. The 
binding site for Bio-LacR and primers used for quantification of plasmids in plasmid 
pull-down experiments are indicated. 
(D) Accumulation of ICLs on SJG-136 treated plasmids assessed using BamHI digestion. 
Plasmids were run on ethidium-bromide agarose gel before (upper panel) or after 
BamHI digestion (lower panel). With increasing doses of the drug, plasmids become 
refractory to BamHI digestion. 
(E) The number of ICLs induced on plasmids treated with SJG-136 was estimated from 
quantification of BamHI digestion products. Results represent quantification from 3 
independent experiments ± SD. 
(F) Representative figure of the quantification of plasmids recovered from extracts after 
pull-down experiments using qPCR. Results represent technical triplicate ± SD from 
a single representative experiment. This analysis was used as a loading control to 
ensure equivalent amounts of plasmids were loaded on gels for Western blot.  
(G) SJG-136 treated plasmids were incubated in HSS, and soluble extracts were analyzed 





Figure S2-2. MutSa and PCNA mutants cloned and purified 
(A) Schematic of X.l. MSH6. The domain structure of this protein and the locations of 
mutations used in the study are illustrated. 
(B) The sequence of the conserved FXE domain in MSH6 is illustrated for several 
species. The amino acid substitutions used in this study are indicated in red. 
(C) The sequence of the conserved PIP domain in MSH6 is illustrated for several species. 
The triple amino acid substitution used in this study is indicated in red. 
(D) Purified MutSaWT, MutSaFXE, or MutSaPIP complex stained with Coomassie blue.  
(E) The sequence of the conserved interdomain connector loop of PCNA is illustrated for 
several species. The double amino acid substitution used in this study is indicated in 
red. 
(F) Purified PCNAWT and PCNAL126A,I128A stained with Coomassie blue. 
(G) Co-immunoprecipitation of purified recombinant WT and mutant MSH2-MSH6 and 
PCNA using preimmune and purified IgG- or MSH2-specific antibodies. 
Immunoprecipitates were analyzed by Western blot with the indicated antibodies (left 
panel). The combination of MSH2-MSH6 and PCNA mutants analyzed are indicated 
in the table (right panel).  
(H) PCNA immunodepletion. Mock- and PCNA-depleted HSS was analyzed by Western 
blot with the indicated antibodies to demonstrate depletion of PCNA. 
(I) Quantification of ICL repair in Mock-, PCNA-depleted, or PCNA-depleted HSS 
supplemented with recombinant PCNAWT, or PCNAL126A,I128A at 3 hrs. Results 







Figure S2-3. Nicking sites on the ICL plasmid and purification of MutLa 
(A) Sequence surrounding the trimethylene GpC-ICL lesion, and the specific locations of 
near (top) and far (bottom) nicking sites used in Figure 2-3A,B. 
(B) Schematic of X.l. PMS2. The domain structure of this protein and the locations of 
mutations used in the study are illustrated. 
(C) The sequence of the conserved catalytic nuclease domain in PMS2 is illustrated for 
several species. The amino acid substitution used in this study is indicated in red. 
(D) Purified MutLaWT and MutLan.d. complex stained with Coomassie blue. 
(E) Plasmid pull-down assay of SJG-136 treated plasmids in MLH1-depleted extract 
(left), or HSS supplemented with MutLaWT and MutLan.d. (right). Plasmid-bound 





Figure S2-4. RPA is required for RIR 
(A) Schematic of X.l. EXO1. The domain structure of this protein and the locations of 
mutations used in the study are illustrated. 
(B) Control or SJG-136 ICL oligonucleotide duplexes run on a denaturing 
polyacrylamide gel and stained with SYBR Gold. 
(C) RPA immunodepletion. Mock- and RPA-depleted HSS was analyzed by Western blot 
to demonstrate depletion of RPA. 
(D) Quantification of ICL repair in Mock-, RPA-depleted, or RPA-depleted HSS 
supplemented with recombinant RPAWT at 3 hrs. Results represent mean ± SEM of 
n=4 independent experiments. 
(E) Purified RPAWT stained with Coomassie blue. 
(F) Plasmid pull-down assay of SJG-136 treated plasmids in Mock- or RPA-depleted 



















































































Figure S2-5. Sequences of site specific trimethylene and NM-like ICL plasmids 
(A) Sequence of oligonucleotide duplexes with a single trimethylene 5’ GpC-, 5’ CpG-, 
or NM-like ICLs.  
(B) Schematic of plasmids containing single site-specific trimethylene 5’ GpC- or 5’ 
CpG-ICL. Plasmids were generated by ligating trimethylene oligonucleotides in (A) 



















Supplemental experimental procedures 
 
Xenopus cell-free extract and depletions 
HSS cell-free extracts were prepared exactly as described previously (Shechter et al., 
2004). Immunodepletions were performed using rabbit anti-MSH2 (Kawasoe et al., 
2016), rabbit anti-MLH1 (Kawasoe et al., 2016) rabbit anti-RPA (Williams et al., 2012), 
and rabbit anti-EXO1 (Liao et al., 2011) antibodies. In each case, antibodies were 
coupled to proteinA sepharose CL-4B beads (Amersham Biosciences) in a 1:3 ratio of 
bed-volume of beads to serum, overnight. Two to three rounds of depletion were 
performed, each for 20 min at 4°C. This was followed by a 10 min clearing round with 
un-coupled proteinA sepharose CL-4B beads. Mock-depleted extracts were prepared 
identically with pre-immune serum. PCNA depletions were performed as previously 
described (Williams et al., 2012), using a p21 peptide (MTDFYHSKRRLIFS) 
immobilized onto a SulfoLink column (Pierce Biotechnology). In all cases, the quality of 
depleted extract was tested by running 0.5 µL of extracts on SDS-PAGE followed by 
Western blot.  
 
ICL Repair assays using quantitative PCR 
ICL repair assays in HSS extracts were performed as described previously (Williams et 
al., 2012). To measure ICL repair, the plasmids recovered from HSS were digested with 
restriction enzymes (PvuI and PvuII for ICLs in pBS backbone and Ndel and DraIII for 
ICLs in pEGFP) prior to qPCR analysis. qPCR was carried out using an Applied 
Biosystems 7500 fast thermocycler with Absolute Blue QPCR SYBR Green low ROX 
PCR mix (Abgene, Cat. #AB-4322B). For experiments involving NM-like ICL lesions 
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TaqMan Fast Advanced Master Mix (Thermo Scientific Cat. #4444964) was used (Figure 
2-5E only).  
 
The cycling conditions used were as follows: ABsolute Blue QPCR Mix: 50°C for 2 min, 
95°C for 15 min followed by 40 cycles of 95°C for 15 sec, 62°C for 30 sec. TaqMan Fast 
Advanced Master Mix: 50°C for 2 min, 95°C for 20 sec followed by 40 cycles of 95°C 
for 3 sec, 62°C for 30 sec. Primers and probes were as follows:  
 
pBS “C” region: 5’ – CTACGGCTACACTAGAAGGACAG and 5’ – 
CCACTGAGCGTCAGACCC 
pBS “X” region: 5’ – CGAGATAGGGTTGAGTGTTGTTC and 5’ – 
ACTAGTTCTAGAGCGGCTGAGG 
pEGFP “C”: 5’ – CTACGGCTACACTAGAAGGACAG and 5’ – 
CCACTGAGCGTCAGACCC 
pEGFP “X”: 5’ – GGGCGTGGATAGCGGTTTGACTCACG and 5’ – 
ATCCCGGGCTGAGGTAGA 
 
TaqMan “C” Probe: 5’ – 6-FAM-TGCAAGCAGCAGATTACGCGCAGAAAA-QSY7 
TaqMan “X” Probe: 5’ – 6-FAM-CGCCCTGATAGACGGTTTTTCGCCCTTT-QSY7 
 
Lac Repressor plasmid pull-down assays 
Lac repressor plasmid pull-down assays in un-depleted and depleted HSS extracts were 
performed as described previously (Williams et al., 2012). Briefly, plasmids were 
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incubated in HSS (15 ng/µL) for 40 min at 21°C. Plasmids were then purified from 
extracts using M-280 streptavidin dynabeads (Invitrogen Cat. #112.05D) pre-bound with 
purified Bio-LacR protein (gift from Dr. K. Marians, MSKCC). The beads were washed 
in a buffer composed of 10 mM Hepes (pH 7.7), 4 mM MgCl2, 50 mM KCl, 1 mM DTT, 
250 mM sucrose, 50 mM NaCl, and 0.015% Triton X-100. Proteins were eluted from 
dynabeads by boiling for 5 min at 95°C in Laemmli buffer and analyzed by SDS-PAGE 
and Western blot. The quantity of plasmid recovered during pull-down experiments was 
assessed by qPCR and used to normalize loading. 
 
MMR assay 
MMR assays were conducted in HSS double depleted with MSH2 and MSH6 antibodies 
as follows: 1 volume of MSH2 serum and 2 volume of MSH6 serum were bound to 1 µl 
of protein A-Sepharose beads. A total of 0.2 volume of antibody-coupled beads was 
incubated in 1 volume of HSS at 4ºC for 1 hr, and the procedure was repeated once. The 
MMR repair assay of a site specific A:C mispair on pMM1AC was performed exactly as 
previously described (Kawasoe et al., 2016). 
 
Construction of site-specific trimethylene and NM-like ICL plasmids:  
Plasmids containing single site-specific trimethylene ICL (used in Figure 2-1 to 2-4, and 
2-5E) were generated exactly as previously described (Williams et al., 2012). Briefly, 
control or trimethylene crosslinked oligonucleotide duplexes (a gift from Dr. C. Rizzo, 
Vanderbilt University) were ligated into pBS using DraIII and PflmI restriction sites. 
Plasmids containing single site-specific SJG-136 ICL lesion (Figure 2-1) were prepared 
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similarly, except that SJG-136 containing ICL duplexes were prepared as described under 
“Preparation of site-specific SJG-136 ICL oligonucleotides”. Plasmids containing single 
site-specific 8 atom, non-distorting NM-like ICL lesion (Figure 2-5E) was prepared in an 
identical fashion using oligonucleotide duplexes containing a defined NM-like ICL lesion 
(Mukherjee et al., 2014b), but were ligated into pBS using BbSI restriction sites. Finally, 
plasmids containing single, site-specific trimethylene GpC- and CpG- ICL lesions used in 
Figure 2-5B-D were generated by ligating oligonucleotides containing these lesions (also 
from Dr. C. Rizzo, Vanderbilt University) into pEGFP vector using AccI and BlpI 
restriction sites. In all cases, closed circular plasmids were purified away from linear and 
nicked ligation products by cesium chloride density ultracentrifugation.  
 
Preparation of site-specific SJG-136 ICL oligonucleotides 
The following oligonucleotides were annealed in equimolar ratio: 5’ 
ATAAAGATCTTTTATCCAATGGCCT and 5’ 
CCATTGGATAAAAGATCTTTATCTA, and phosphorylated using T7 PNK. Single, 
site-specific SJG-136 ICLs were generated by incubating 100 µg of oligonucleotide 
duplex with100 µM SJG-136 in 50 mM triethanolamine and 2 mM EDTA overnight at 
37°C. Samples were ethanol precipitated and re-suspended in formamide loading buffer 
and run on a 20% acrylamide urea-TBE gel at 200 V for 2 hrs. Duplex containing ICLs 
were purified away from uncrosslinked oligos using UV shadowing and gel extraction 
using the crush-soak method as previously described (Enoiu et al., 2012b). Purified 
crosslinked oligonucleotide duplexes were used to prepare plasmids with site-specific 
ICL lesions.  
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Protein expression and purification  
Xenopus laevis MSH2-MSH6 complex was a purified using a method modified from 
(Kawasoe et al., 2016). Briefly, Sf9 cells were co-infected with MSH2 and MSH6WT-
Flag, MSH6PIP-Flag, or MSH6FXE-Flag baculoviruses. Cells were harvested 72 hrs after 
infection and lysed through a syringe in Buffer S: 25 mM Tris-HCl pH 7.4, 250 mM 
NaCl, 5 mM 2-mercaptoethanol, 1 mM EDTA, 2 mM phenylmethylsulfonyl fluoride, 
1 mM benzamidine and 1x cOmplete, EDTA-free (Roche). The crude lysate was cleared 
by centrifugation for 30 min at 30,000 rpm. Cleared lysates were incubated with FLAG-
M2 agarose beads for 3 hrs at 4°C. After washing, MSH2-MSH6 complexes were eluted 
from beads in 50 µg/mL FLAG-peptide in Buffer A (25 mM Tris-HCl pH 7.4, 5% 
glycerol, 5 mM 2-mercaptoethanol, 1 mM EDTA and 0.1x cOmplete, EDTA-free). 
Eluted proteins were dialyzed in fresh Buffer A overnight at 4°C. 
 
Xenopus laevis MLH1-PMS2 was expressed in Sf9 cells by co-infecting cells with 
MLH1-Flag and PMS2WT or PMS2n.d. baculoviruses. Cells were harvested 48-72 hrs after 
infection, and lysed by swirling gently in Buffer S. The purification procedure was 
similar to that described for MSH2-MSH6 complex except that the protein complex was 
eluted with 50 µg/mL Buffer D: 25 mM Tris-HCl pH 7.4, 50 mM NaCl, 10% glycerol, 5 
mM β-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, and 2 mM Benzamidine.  
 
Xenopus laevis His-tagged EXO1WT and EXO1D173A protein was expressed and purified 
as previously described (Liao et al., 2011).  
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Xenopus laevis 6xHis-tagged PCNA was expressed and purified from BL21 cells exactly 
as previously described (Williams et al., 2012).  
 
Xenopus laevis RPA complex was purified from the soluble fraction of BL21 lysate using 
standard Flag-purification protocol. Polycistronic RPA vector was originally obtained 
from Dr. K. Cimprich (Stanford University).  
 
hExo1 catalytic domain (residues 1–352) was as purified from E. coli BL21(DE3)RIL as 
described previously (Shi et al., 2017). Cells were grown in 10 L Luria Broth (with 100 
g/ml ampicillin) for 16 hr at 16 °C after induction with 0.1 mM IPTG; and harvested by 
centrifugation (4000 × g, 4°C, 30 min). The harvested cells were resuspended in lysis 
buffer (50 mM HEPES-NaOH, pH 7.5; 100 mM NaCl; 10 mM KCl; 5 mM MgC2l2; 5 
mM DTT; 1 mM EDTA; 10% glycerol), and lysed with a cell cracker (Microfluidics). 
The lysate was cleared by centrifugation (18,500 × g, 4°C, 30 min) and loaded onto two 
tandem 5 ml HisTrap HP Ni Sepharose column (GE Healthcare Life Sciences) pre-
equilibrated with wash buffer (lysis buffer with 300 mM NaCl and 20 mM imidazole). 
The protein was eluted with 300 mM imidazole and pooled. TEV protease was added to 
the protein solution and incubated at 4°C for 12 hrs to cleave the hexahistidine 
purification tag. The cleaved mixture was loaded onto pre-equilibrated Ni Sepharose 
column again to remove the hexahistidine purification tag. The eluate was loaded onto 5 
ml HiTrap SP FF column (GE Healthcare Life Sciences) equilibrated in low ion buffer 
(50 mM HEPES, pH 7.5; 100 mM NaCl; 10 mM KCl; 1 mM MgCl2; 5 mM DTT; 1 mM 
EDTA; 5% glycerol). Fractions containing pure protein were then eluted with high ion 
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buffer (low ion buffer plus 500 mM NaCl). The purified protein was exchanged into 
storage buffer (25 mM HEPES-NaOH, pH 7.5; 125 mM NaCl; 10 mM KCl; 1 mM 
TCEP), concentrated to ~20 mg/ml, flash-frozen in liquid nitrogen, and stored at -80°C. 
 
Mutagenesis Primers: Site-directed mutagenesis was used to generate the following 
mutations (QuikChange XL Site-Directed Mutagenesis Kit (Agilent Technologies; Cat. 
#200517) following manufacturer’s instructions. The numbering of mutant residues 
corresponds to the amino acid residue of the Xenopus proteins.  







PMS2E692K – nuclease dead 
• 5’ GATCAGCATGCGACCGATGAGAAATACAACTTTGAGGTTTT 
• 5’ AAAACCTCAAAGTTGTATCTCTTATCGGTCGCATGCTGATC 
PCNAL126A,I128A – IDCL (this mutant was generated from pET28aPCNAwt, a gift from 
Dr. V. Costanzo, IFOM) 
• 5’ GTGGAGCAGGCGGGCGCTCCTGAACAAG 
• 3’ CTTGTTCAGGAGCGCCCGCCTGCTCCAC 
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EXO1352 nuclease assay 
The following oligonucleotides (with or without a biotin moiety on 5’ ends), which 
contain a single SJG-136 ICL reaction site were annealed at equimolar concentrations:  
• 5’ ATAATTTGATCATTATTAT 
• 5’ ATAATAATGATCAAATTAT 
Singly crosslinked oligonucleotides were purified by incubating duplex oligo with 100 
µM SJG-136 overnight at 37°C. Crosslinked oligonucleotides were purified by gel 
extracted using the crush soak method. 25 ng control or crosslinked oligos were 
incubated with 0-100 nM EXO1-352 in nuclease reaction buffer (20 mM Tris HCl, 0.7 
mM Hepes-KOH, 120 mM KCl, 5 mM MgCl2, 250 µg/mL BSA, 1.5 mM ATP, 1 mM 
glutathione, 60 µM DTT, 1% glycerol) for 30 min at 37°C in a 5 µL total volume. The 
reaction was stopped with the addition of formamide loading buffer, before running on a 
12% acrylamide urea gel. Gels were stained with SYBR Gold.  
 
Antibodies used for Western blot 
The following antibodies were used for Western blot of Xenopus extracts: PCNA (Sigma-
Aldrich Cat. #P8825), Histone H3 (Cell signaling Cat. #9715S), and Flag M2 (Millipore 
Sigma Cat. # F1804), MSH6 (X.l.) (Olivera Harris et al., 2015), MSH2 (X.l.) (Olivera 
Harris et al., 2015), EXO1 (X.l.) (Liao et al., 2011), RPA 70 (X.l.) (Williams et al., 2012), 
FANCI (X.l.) (Williams et al., 2012), MLH1 (X.l.) (Kawasoe et al., 2016), and PMS2 













Discussion and Future Directions 
 
Cells have evolved multiple repair pathways to remove ICL lesions from their 
genomes. The mechanism by which ICLs become destined for repair is determined not 
only by cell cycle, but also dependent on the transcription status of the DNA in which it 
lies. Moreover, repair pathway choice can be further influenced by the structure and 
chemistry of ICLs, and the level of distortion it imparts on the DNA molecule. 
Despite this complexity, the field has made outstanding progress over the last 10 
years in elucidating the molecular details by which cells respond to and repair these 
lesions (Figure 3-1). In rapidly dividing cells, replication is the primary mechanism of 
ICL detection. ICLs that are amenable to direct cleavage by NEIL3, such as Ap-ICLs and 
psoralen ICLs are processed quickly and efficiently without the generation of DSB repair 
intermediate (Semlow et al., 2016). The preference of NEIL3 for psoralen and Ap-ICLs 
may reflect an evolutionary bias for ICLs that occur more commonly as a result of 
cellular metabolism. A slower, and more complex method of repair occurs for cisplatin- 
and MMC-ICLs, which are not amenable to processing by NEIL3. In this modality of 
repair, the entire FA pathway and the HR machinery must cooperate to fully repair ICL 
lesions in a multi-step repair reaction that also involves the repair of a DSBs intermediate 
(Räschle et al., 2008). While S-phase repair of ICLs is complex in itself, there is one key 
simplifying factor: during RCR, all ICLs regardless of structure, are recognized by the 
replication machinery.  
In cells that are not dividing, this critical step is a more complex task. If the ICL lies 
in a transcriptionally active locus, it may be recognized through collision with the 
transcription machinery. However, ICLs can also occur in less-active regions of the 
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genome, and can interfere with processes such as transcription factor binding. These ICLs 
must be recognized through surveillance mechanisms by DNA damage sensor proteins, 
and funneled into a repair pathway. However, the precise proteins involved, and the 
mechanisms by which they contribute to repair process have remained elusive during this 
process. 
Our lab previously established the Xenopus laevis extract system to study replication 
and transcription independent ICL repair (Ben-Yehoyada et al., 2009; Williams et al., 
2012). This system has been instrumental in establishing RIR as a bone fide ICL repair 
pathway, with distinct molecular requirements for ICL repair compared to RCR. Indeed, 
RIR does not require the FA proteins, the HR machinery, or the TLS polymerase, Pol z 
(Williams et al., 2012), but instead requires TLS polymerase Pol κ and PCNA (Williams 
et al., 2012).  
In this thesis, I used this system to examine the contribution of DNA repair proteins 
from multiple diverse pathways including MMR (Chapter 2 and Appendix B), NER 
(Appendix E), DSBR (Appendix D), and TLS (Appendix C). Our studies identify 
additional molecular components of RIR, and also shed significant insight into the 
enzymatic unhooking and processing of ICLs during RIR.  
Most notably, in Chapter 2, we show that the MMR machinery is an important 
contributor of RIR. We show that in the absence of replication and transcription, the 
MutSa (MSH2-MSH6) complex binds and recognizes ICLs. MutSa recruits various 
downstream repair proteins including the MutLa endonuclease, and the EXO1 
exonuclease to sites of damage. And the catalytic activity of both of these nucleases are 
required to process ICLs. Together our data unambiguously demonstrate that the MMR 
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proteins contribute to the productive repair of ICLs, an idea that has been controversial to 
date.  
We have demonstrated that structurally distinct ICLs are repaired during RIR 
(Chapter 2 and Appendix A), albeit with varying efficiencies. These include the 
trimethylene-ICLs in two conformations (GpC and CpG), as well as the Ap-ICL. The 
non-distorting NM-like ICL had no detectable levels of repair.  
These observations support my hypothesis that during RIR, helix distorting ICLs are 
more amenable to recognition by DNA damage sensor proteins, and are repaired with 
better efficiencies than ICLs which do not alter the structure of the DNA molecule. To 
further corroborate this idea, it would be interesting to also compare the repair kinetics of 
additional ICL types such as the cisplatin ICL, the 5- and 6- atom linker NM-like ICLs 
analogs, and the Ap-ICL in multiple different conformations.  
In addition to ICL structure, ICL repair kinetics can be reflective of the actions of 
different DNA damage sensor proteins. While we extensively investigated the role of 
MutSa in Chapter 2, we have not yet explored the contribution of MutSb, XPC, and 
DNA glycosylases (such as NEIL3) during RIR. It is clear that MutSa is a major sensor 
of trimethylene-ICLs, but it is likely that other structurally distinct ICLs may be more 
amenable to detection by these other DNA damage sensor proteins. In fact, my 
preliminary studies with Ap-ICLs show that these lesions are repaired independently of 
MSH2 (Appendix A), and are a good candidate for repair by the NEIL3 glycosylase.  
Given that all the aforementioned DNA repair proteins (MutSa, MutSb, XPC, and 
NEIL3) are known to participate in the repair of other DNA lesions, it would be 
important to study the crystal structures of the proteins bound to ICLs. These studies 
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could shed insight into whether mechanism of DNA damage recognition is conserved 
between repair pathways. Indeed, our data suggest the mechanism of DNA damage 
recognition by MutSa is conserved between MMR and RIR since both processes are 
dependent on the FXE motif in MSH6.  
Our studies using nicked ICL plasmids (trimethylene and NM-like ICLs) show that a 
single 5’ incision ~20 based away from the ICL site is able to stimulate ICL repair. This 
observation has several implications. First, these experiments demonstrate that incision 5’ 
to the ICL is a rate-limiting step during RIR. Second, the asymmetry between 5’ and 3’ 
incisions on repair kinetics could reflect the action of 2 distinct nucleases. Finally, these 
experiments suggest that incision ~20 bases away from an ICL is optimal for its repair 
and could reflect the physiological site of incision.  
The stimulatory asymmetry between 5’ and 3’ incisions on ICL repair rate is 
conserved between trimethylene (Chapter 2) and NM-like ICLs (Figure A1 B). These 
results are interesting as it points to a unique mechanistic phenomenon, specific to ICL 
repair. During MMR, a single nick either 5’ or 3’ is able to stimulate repair, and this 
stimulation is observed even when nicking occurs hundreds of bases away from the 
mispaired site. It would be interesting to test whether repair or other ICLs is also 
stimulated by a 5’ incision.  
The 5’ nick-directed repair of NM-ICLs is very robust, and warrants further 
investigation. For example, it would be informative to conduct depletion-rescue 
experiments using the 5’ nicked NM-ICL repair to determine whether its repair requires 
components of the MMR pathway (particularly MutLa) and/or TLS Pol k. In RCR, the 
cisplatin and NM-like ICLs requires Pol z and Rev1 for lesion bypass (Räschle et al., 
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2008). If the requirement for TLS is dependent foremost on lesion structure, the NM-ICL 
may also require these polymerases during RIR. 
Finally, multiple NM ICLs have been synthesized in various different conformations 
(Guainazzi et al., 2010; Mukherjee et al., 2014a), from completely non-distorting (8-atom 
NM linker) to moderately distorting (5-atom NM linker) (Mukherjee et al., 2014a; Roy 
and Schärer, 2016). The studies described herein only pertain to the 8-atom NM linker. It 
would be interesting to study the other NM-ICL analogs to further study how ICL 
structure affects its repair during RIR.  
While our experiments with the nicked plasmid suggest that incision ~20 bases away 
from the ICL is a physiologically relevant sight of incision, it would be informative to 
examine the precise location of this incision site during RIR in HSS.  
For this, a single strand ligation mediated PCR (sslm-PCR) and high throughput 
sequencing could be useful (Figure 3-2). During processing of an ICL site, for instance 
after incision events or repair synthesis events, 3’ hydroxyl ends are generated. These 
free hydroxyl ends are available for ligation with small adapters. Using a forward primer 
complementary to the ICL plasmid backbone, and a reverse primer complementary to 
that of the ligated oligonucleotide, we will be able to use PCR and sequencing to 
characterize each structure at single base pair resolution. Given that single stranded 
byproducts are only obtained upon initiation of repair, results will exclusively represent 
repair species.  
This sslm-PCR approach would not only be useful in mapping sites of 
endonucleolytic incision, but could also be useful to investigate the extent to which 
polymerases contribute to the repair reaction. RIR is thought to involve the sequential 
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action of multiple DNA polymerases including, Pol k. However, it is not known if Pol k 
participates in the synthesis up to or across the unhooked ICL adduct. I hypothesize that 
upon depletion of a Pol k, specific ICL repair intermediates will accumulate, using sslm-
PCR we can learn the extent to which Pol k participates during TLS.  
Finally, while the Xenopus extract system is a powerful system to study the 
mechanism of RIR, it would be exciting to extend our studies to mammalian cells. For 
this, it would be important to use terminally differentiated, non-dividing cells such as 
neurons. Various approaches including immunofluorescence to monitor recruitment of 
repair proteins to crosslinker treated cells, or monitoring ICL repair using ICL-specific 




Many studies have suggested that diverse DNA repair pathways contribute to the RIR 
of DNA interstrand crosslinks. However, the precise proteins involved, and the 
mechanisms by which they contribute to repair process have remained largely elusive. 
My studies using structurally defined ICL substrates in Xenopus cell free extracts lends 
insight into how the MMR helps identify and process ICL lesions in cells that are non-
dividing.  
Taken together, these studies contribute profoundly to our understanding of how cells 
respond to and repair ICL lesions throughout the cell cycle. Better understanding how 
these mechanisms cooperate or compete to remove ICLs will help develop better 
crosslinker based chemotherapies.  
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Chapter 3 Figures 
 
  
Figure 3-1. Mechanism of ICL repair 
ICLs are repaired throughout the cell cycle. ICL repair during S-phase is triggered by the 
replication machinery, which collides with the damage site, and funnels the lesion into 
repair either by a glycosylase- or FA-dependent mechanism. Outside of S-phase ICL 
recognition is either accomplished by the transcription machinery, or by DNA damage 
sensor proteins. The molecular components and mechanisms of repair are significantly 






Figure 3-2. Mapping sites of ICL processing using sslm-PCR 
(A) Schematic of ICL plasmid and the site of stimulatory 5’ incision event 
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Appendix A. Structure Specific Repair of ICLs during RIR 
 
Niyo Kato, Jean Gautier 
 
Our studies using Xenopus HSS extracts in Chapter 2 demonstrate that structure is a 
key determinant of ICL repair efficiency during RIR. Briefly, we compared trimethylene 
ICLs in two structural conformations (more distorting GpC-ICL vs less distorting CpG-
ICL), and found that the more distorting lesion led to a more robust DNA damage 
checkpoint activation, and was repaired 40% more efficiently than its less distorting 
counterpart. Moreover, a non-distorting NM-like ICL remained unrepaired over the 
course of 3-4 hours, a timespan in which trimethlyene ICLs undergo robust repair. 
Together these results suggest that more distorting ICLs are more amenable to 
recognition and hence repair, in the absence of replication and transcription. 
Here, we build on this idea in two ways. First, we show that the NM-like ICL lesion 
can be stimulated to repair at 30-40 fold (corresponds to increase in repair from 0 to  
~10% repair) better efficiency with a single nick ~25 bases 5’ to the ICL site compared to 
un-nicked substrate (Figure A1 A,B). An incision at a similar distance 3’ (27 bases away) 
to the lesion has no effect on repair kinetics. Because incision events are thought to be the 
first catalytic event during RIR, these experiments suggest that a single nick can help 
bypass the requirement for NM-ICL recognition. It further suggests that sensing of NM-
ICLs is a key rate-limiting step for its repair, further supporting the hypothesis we pose in 
Chapter 2, that MutSa favors DNA lesions that are more distorting.  
We have also studied the repair of an Ap-ICL lesion (Figure A2 A). The repair of this 
Ap-ICL was recently studied in the context of replication by the Walter lab (Semlow et 
al., 2016). Unlike the cisplatin and NM-ICLs which require the FA machinery for repair, 
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the authors show that Ap-ICLs undergo direct cleavage by the NEIL3 DNA glycosylase. 
The authors conclude that Ap-ICLs only repair during replication, as inhibition of 
replication in HSS+NPE (replicating Xenopus extracts) by geminin inhibited ICL repair 
in their repair assays, (Southern blot and radionucleotide incorporation assays). 
Nevertheless, it remains possible that Ap-ICLs are repaired in the absence of replication 
at low levels that are undetectable using these methods. 
We use a more sensitive qPCR based assay to determine whether Ap-ICLs are 
repaired in non-replicating HSS extracts. We find that Ap-ICLs are rapidly repaired in 
HSS (Figure A2 B), and that the repair of these lesions occurs on both strands of the 
DNA molecule. This is determined by BglII restriction enzyme digestion of the ICL 
plasmid after incubation in HSS extract, where completion of ICL repair results in the 
production of a BglII restriction site. 
Unlike trimethylene-ICLs in HSS, the repair of Ap-ICLs is not dependent on MMR, 
as depletion of MSH2 or MLH1, has no impact on the repair of Ap-ICLs (Figure A2 
C,D). This suggests that Ap-ICLs are not amenable to detection by MutSa, and are 
further not processed by the MMR machinery. Ap-ICLs likely rely on the function of 
other DNA damage sensor proteins, perhaps XPC or NEIL3 (or other) which triggers a 
mechanistically distinct ICL repair process. Not surprisingly, this process still relies on 
PCNA for efficient repair (Figure A2 E), suggesting and TLS repair is a critical event 
during the repair of Ap-ICLs. Moreover, if Ap-ICLs are in fact processed by NEIL3 in 
RIR, PCNA depletion would only result in a 50% repair phenotype as measured by our 
qPCR based assay: upon cleavage of an Ap-ICL by NEIL3 the DNA will resolve into one 
intact DNA strand, with the opposing DNA strand containing a single abasic lesion. 
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Further studies are needed to determine which DNA damage sensor proteins are 
required for the recognition of Ap-ICLs in HSS extracts, and to determine what other 











Figure A 1. Nicking experiments with NM-like ICL in HSS 
A. Sequence surrounding the NM-like ICL lesion, and the specific locations of nicking 
sites used in (B). 
B. Quantification of repair of NM-like ICL lesion in HSS at 40 min. Repair is only 

































Figure A 2. Repair of Ap-ICL in HSS 
A. Sequence of Ap-ICL oligo.  
B. Quantification of Ap-ICL repair in HSS extract at the indicated time points (Mock). 
Repaired plasmids, which were recovered from HSS extracts, were digested with 
BglII to monitor whether ICL repair occurred to completion.  
C. Quantification of Ap-ICL repair in Mock- and MSH2-depleted HSS at 3 hrs. Results 
represent mean ± SEM from two independent experiments. 
D. Quantification of Ap-ICL repair in Mock- and MLH1-depleted HSS at 3 hrs. Results 
represent mean ± SEM from three independent experiments. 
E. Quantification of Ap-ICL repair in Mock- and PCNA-depleted HSS at 3 hrs. Results 



























































Appendix B. MMR Deficient Mammalian Cells are Sensitive to MMC 
 
Niyo Kato, Jean Gautier (unpublished) 
 
Our results in Xenopus extracts (Chapter 2) indicate that ICL repair in non-replicating 
extracts harness components of the MMR pathway. If this pathway is also operative in intact 
cells, the loss of MMR should increase cell susceptibility to crosslinking drugs.  
To test this prediction, I generated MCF10A cells lines stably expressing constructs in which 
doxycycline-inducible shRNA mediates knockdown of either MSH6 or PMS2. MCF10A cells 
were chosen because they are non-transformed and near-diploid breast epithelial cells, and 
therefore offer a clean system to study drug sensitivity.  
MSH6 and PMS2 were efficiently knocked-down 72 hours after addition of doxycycline to 
growth media, as shown by Western blot (Figure B1 A-C). These cells were treated with MMC, 
which induces a crosslink similar in structure to the trimethylene-GpC-ICL lesion we assayed in 
HSS extracts. Cells were exposed for drug for 3 hours, followed by growth for 12-15 days in the 
presence of doxycycline. Both MSH6- and PMS2- deficient cells were more sensitive to MMC 
compared to control cells with scramble shRNA (Figure B2 A,B). These results support our in 
vitro findings that MMR proteins cooperate to recognize and remove ICLs. These results are 
consistent with several previous studies that correlate the loss of MutSa or MutLa to MMC 
sensitivity (Fiumicino et al., 2000; Huang et al., 2011; Peng et al., 2014). 
It is important to point out that MutSa deficiency has also been linked to cisplatin-resistance 
(reviewed in (Jung and Lippard, 2007). This phenotype is unique to cisplatin, and not observed 
when cells are treated with other platinum drugs including oxaliplatin (Jung and Lippard, 2007), 
or crosslinkers such as NMs and MMC (Fiumicino et al., 2000). The differences in cellular 
responses to these drugs, measured by survival in these experiments, therefore likely reflects the 
diverse ways in which cells respond to structurally distinct ICLs or the other DNA adducts that 
these chemicals also generate. Hence, inferring the contribution of DNA repair proteins from 
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Figure B 1. shRNA mediated knockdown of MSH6 and PMS2 in MCF10A cells 
A. Western blot analysis of MCF10A whole-cell lysate to demonstrate knockdown of 
MSH6 72 hrs after addition of doxycycline to cell growth media. 
B. Western blot analysis of MCF10A whole-cell lysate showing efficient MSH6 
knockdown with three shRNA clones. Clones A and B were used for clonogenic 
survival assays. 
C. Western blot analysis of MCF10A whole-cell lysate showing efficient PMS2 




























Figure B 2. Sensitivity of MSH6- and PMS2-deficient MCF10A cells to mitomycin C 
A. Clonogenic survival assay of MSH6-deficient human breast epithelial MCF10A cells 
in the presence of indicated doses of MMC. Results represent the mean ± SEM of at 
least three independent experiments. 
B. Clonogenic survival assay of PMS2-deficient human breast epithelial MCF10A cells 
in the presence of indicated doses of MMC. Results represent the mean ± SEM of at 






































Appendix B. Methods 
 
Cell Culture and production of MCF10A cells with stable integration of doxycycline 
inducible shRNA 
 
MCF10A cells were cultured in DMEM-F12 (Invitrogen) supplemented with 5% 
horse serum (Invitrogen), 20 ng/mL EGF (Peprotech), 0.5 µg/ml hydrocortisone (Sigma- 
Aldrich Corporation), 100 ng/mL cholera toxin (Sigma), 10 µg/ml insulin (Sigma), and 
Pen Strep (Invitrogen). 293T cells were cultured in DMEM (Invitrogen) and Pen Strep 
(Invitrogen), supplemented with 10% FBS (Invitrogen). All cells were incubated at 37°C 
with 5% CO2. The following doxycycline inducible shRNA clones (Dharmacon) 
targeting MSH6 (MSH6-A: V3THS_318784 and MSH6-B: RHS4696-101352772) and 
PMS2 clones (PMS2-C: V3THS_302063 and PMS2-D: V2THS_93546) were used. Each 
shRNA vector was purified using E.Z.N.A. Plasmid Miniprep kit (Omega Bio-Tek, Inc.) 
and packaged into lentiviruses by transfecting (jetPEI by Polyplus-transfection) into 293T 
cells with pMD.G and pCMVR8.91. After 24 hrs, the media was replaced with MCF10A 
media, which was used to collect viruses at the 48 hr timepoint. Viruses were filtered and 
were used to infect MCF10A cells by spin infection; 1 hr at 1000 rpm at RT in the 
presence of 8 µg/ml polybrene (Sigma). After 24 hrs of incubation, infected cells were 
selected by the addition of 2 µg/ml puromycin (Sigma). For Western blot of MCF10A 
whole-cell lysates, cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% Na-
DOC, 0.1% SDS, 50 mM Tris pH 8.0), supplemented with protease and phosphatase 
inhibitors (Sigma), for 10 min on ice.  
 
Clonogenic Survival Assays 
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Cells were induced to express shRNA against MSH6 or PMS2 with addition of 1 
µg/mL doxycycline in growth media. After 72 hrs, cells were plated at a density of 300 
cells per 100 mm plate and allowed to adhere for 1 hr. Cells were treated with MMC for 
3 hrs, and then grown in fresh media for 14 days. Throughout the experiment, cells were 
grown in 1 µg/mL doxycycline, which was added to the media every three days. Colonies 
were fixed with methanol and stained with crystal violet. Cell survival was calculated as 




Appendix C. The Role of Pol d, Pol e, and Rev1 in RIR 
 
Niyo Kato, Hannah Williams, Jean Gautier (unpublished) 
 
ICL repair is thought to involve the sequential action of multiple DNA polymerases. 
The first polymerase is thought to synthesize up to or across the unhooked ICL adduct, 
while a second polymerase is thought to extend from the often mispaired/distorted DNA 
junction.  
During RCR in S-phase, the replicative DNA polymerases Pol d and Pol e, as well as 
the TLS Pol z and Rev1 are important for ICL repair. Indeed, in replicating Xenopus 
extracts, the Walter lab has shown that Pol d and Pol e are retained on ICL-containing 
plasmids, and that the Pol z and Rev1 are required for the extension phase of repair 
synthesis (Budzowska et al., 2015; Räschle et al., 2008).  
In contrast, during RIR in non-replicating Xenopus HSS extracts, our lab has 
previously demonstrated that Pol z is dispensable for trimethylene ICL repair, as 
depletion of Rev7, the catalytic subunit of Pol z had no impact on ICL repair in HSS 
(Williams et al., 2012). Instead, we found that Polk and monoubiquitinated PCNA is 
essential for repair synthesis reaction.  
We now directly interrogate the contribution of the DNA polymerases Pol d and Pol 
e, as well as Rev1 during RIR in HSS extracts. Pol d and Pol e are replicative 
polymerases, best known for their involvement in leading and lagging strand synthesis 
reactions during replication. They are intricately linked to RCR, as replication fork 
convergence is a requirement to trigger ICL repair during S-phase (Zhang et al., 2015). 
Rev1 is a deoxycytidyl transferase, and a member of the Y-family of translesion 
sysnthesis DNA polymerases. Rev1 has been linked to ICL repair in several studies 
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(Budzowska et al., 2015; Räschle et al., 2008). Cells deficient for Rev1 are extremely 
sensitive to crosslinker drugs (Kim and D’Andrea, 2012), and have defects in repairing 
psoralen, MMC (Shen et al., 2006), and cisplatin ICLs (Enoiu et al., 2012a). These 
studies, which use a plasmid based luciferase reporter assay with a site-specific ICL 
between the CMV promoter and a luciferase reporter, suggests that Rev1 plays a key role 
during transcription initiated ICL repair, in addition to its role during RCR.  
We immunodepleted Pol d, Pol e, and Rev1 from HSS extracts (Figure C 1A), and 
conducted ICL repair assays. Pol d and Pol e antibodies were generous gifts from Shou 
Waga. Rev1 antibodies were a gift from Johannes Walter.  
In these extracts, we monitored the repair of the trimethylene-GpC-ICLs. 
Interestingly, depletion of Pol d, enhanced ICL repair compared to mock-depleted 
extracts (Figure C1 B). This suggests that Pol d eviction from sites of ICL repair may be 
important for the recruitment of TLS polymerases during repair. In contrast, depletion of 
Pol e resulted in ~50% reduction in ICL repair capacity (Figure C1 C). Pol e may 
therefore contribute to ICL repair during RIR. Of note, the specificities of these defects 
have not been established in a depletion-rescue experiment with recombinant Pol d and 
Pol e protein.  
Finally, the level of ICL repair between Mock and Rev1-depleted extracts were 
comparable, strongly suggesting that Rev1 does not contribute to the repair of 
trimethylene ICLs during RIR (Figure C1 D). A similar result was obtained for Ap-ICL 
in Mock and Rev1-depleted extracts (Figure C1 E). These results are consistent with our 
previous data that a Rev1 binding deficient Polκ F562A,F563A fully rescued repair of the 
trimethlyene-GpC ICLs in HSS (Williams et al., 2012).  
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Further studies are needed to determine whether Rev1 contributes to the repair of 
other, structurally distinct ICLs during RIR. It would be particularly informative to test 












Figure C 1. The role of Rev1 during RIR 
A. Pol d, Pol e, and Rev1 immuno-depletions. Mock-, Pol d-, Pol e-, and Rev1-depleted 
HSS were analyzed by Western blot to confirm depletions. Pol d was immuno-
depleted using 2 rounds of p125 followed by 2 rounds with p66 antibody (1:3:3 ratio 
of beads : serum : HSS). Pol e was depleted in 4 rounds of pol e serum (1:2:3 ratio of 
beads : serum : HSS). Rev1 was efficiently immuno-depleted from HSS as previously 
described (Budzowska et al., 2015). 
B. Quantification of trimethylene-ICL repair in Mock- and Pol d-depleted HSS at 3 hrs. 
Results represent mean ± SEM from two independent experiments. 
C. Quantification of trimethylene-ICL repair in Mock- and Pol e-depleted HSS at 3 hrs. 
Results represent mean ± SEM from two independent experiments. 
D. Quantification of trimethylene-ICL repair in Mock- and Rev1-depleted HSS at 3 hrs. 
Results represent mean ± SEM from two independent experiments 
E. Quantification of Ap-ICL repair in Mock- and Rev1-depleted HSS at 3 hrs. Results 
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Appendix D. The Role of CtIP in RIR 
 
Niyo Kato, Jean Gautier (unpublished) 
 
CtIP plays a critical role double strand break repair. Together with the MRN complex 
(Mre11, Rad50, and Nbs1), CtIP promotes DNA end resection in response to double strand 
breaks, biasing the repair of the damage lesion into homology directed repair processes 
(Symington and Gautier, 2011).  
Recent studies show that CtIP has an additional, MRN independent role during replication 
coupled ICL repair (Murina et al., 2014; Unno et al., 2014). These studies reveal that CtIP is 
recruited to chromatin in response to treatment with MMC, in a FA dependent manner. Cells 
deficient in FA proteins have deficient CtIP foci formation in response to MMC. CtIP binds the 
core Fanconi Anemia protein FANCD2, and this interaction helps localize CtIP to ICL lesions, 
early in the ICL repair process. CtIP helps suppress repair of ICL-induced double strand breaks 
by NHEJ, and promote homology directed repair processes (Murina et al., 2014; Unno et al., 
2014). Importantly, these studies also show that CtIP depleted cells are sensitive to MMC and 
have increase gross chromosomal aberration, a hallmark of FA cells. 
In contrast to RCR, double strand breaks are not generated during RIR. The requirement for 
DNA resection to promote homology directed repair is therefore absent. However, during RIR 
nucleolytic processing of ICL repair intermediates are thought to occur.  
To determine whether CtIP contributes to ICL repair outside of replication, I conducted 
depletion rescue experiments ICL plasmids containing a single site-specific trimethylene-GpC 
ICL lesion in HSS. CtIP was efficiently immuno-depleted from HSS using CtIP specific 
antibodies (gift from Richard Baer) (Figure D 1A). ICL repair in CtIP depleted extracts were 
similar to that of mock-depleted extracts, indicating that CtIP does not contribute to ICL repair 












Figure D 1 The role of CtIP during RIR 
A. CtIP immunodepletion. Mock- and CtIP-depleted HSS were analyzed by blot to 
confirm depletion of CtIP. 
B. Quantification of trimethylene-GpC-ICL repair in Mock- and CtIP-depleted HSS at 3 























Appendix E. Homemade Antibodies 
 
Xenopus extracts are a powerful system to study DNA damage and repair 
mechanisms. Extracts provide a unique opportunity to study the function of a given 
protein by removing the protein from the extract without resulting in lethality. Protein-
depletion requires multiple rounds of depletion using high quality antibodies or peptides 
that can specifically and quantitatively deplete a protein from the extracts. 
In order to study the effects of MSH2 and XPC on ICL repair using HSS extracts, I 





I generated antibodies against Xenopus laevis MSH2 essentially as previously 
described by the Takahashi group (Kawasoe et al., 2016). Briefly, a 19 amino acid C 
terminal peptide of X.l. MSH2 (sequence: C+LAKNNRFVSEVISRTKTGL) was KLH-
conjugated (at the C residue) and used to immunize 3 rabbits (Covance): Rabbit-1828, -
1829, and -1830. Serum from all three rabbits were tested for competence for Western 
blot analysis and immunodepletions of MSH2 in Xenopus HSS extracts.  
To test the sera for suitability for Western blot analysis, I checked to see whether each 
serum (1:5000 dilution) would be able to recognize a band corresponding the MSH2 in 
HSS, either mock depleted, or MSH2-depleted using antibodies generated by the 
Takahashi lab. While all three sera are able to detect a band corresponding to MSH2 
(Figure E1 A), probing with the MSH2-1828 serum produces the cleanest signal, without 
any non-specific signal in the vicinity of the MSH2 protein.  
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I also extensively tested each serum to check for their ability to efficiently deplete 
MSH2 from HSS in a series of immunoprecipitation experiments (data not shown), and 
found that serum-1829 and 1830 are best for this purpose. Depletion of HSS with serum-
1830 is able to deplete both MSH2 and MSH6 from HSS using 3 rounds of depletion 
1:3:3 = beads : serum : HSS ratio, followed by a clearing round (Figure E1 B). 
Repair of a trimethylene ICL are defective in ∆MSH2-1830, and this phenotype can 
be rescued with recombinant MutSa complex. MSH2-1830 serum can therefore be used 




Figure E 1. Homemade MSH2 antibodies for Western blot and immunodepletion 
A. Western blot of mock or MSH2 depleted HSS. Extracts were depleted with T. Takahashi 
MSH2 antibodies, and probed with homemade MSH2 serum (all 1:5000 dilution). MSH2-
1828 serum is best for Western blot analysis. 
B. Western blot of HSS depleted with MSH2-1830 serum. MSH2 was probed with J. Jiricny 
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I generated antibody against Xenopus laevis XPC using a protein fragment of XPC 
which I cloned from the X.l. cDNA library. The sequence of X.l. XPC is not available. I 
therefore referenced the Xenopus tropicalis XPC sequence (Xenbase) to design 
degenerate primers to use for the cloning process. 
I cloned a 528 base pair fragment of XPC using PCR and TA cloning into the 
pGEMT vector (Figure E2). This fragment was subsequently His-tagged and subcloned 
into the bacterial expression vector: pProEX HTc. The ~25KDa XPC fragment was 
induced to express in BL21 cells with IPTG overnight, before being purified from 
bacterial lysate (Sambrook and Green, 2012).  
Purified XPC fragment was further gel purified, and was used to immunize three 
rabbits (Covance): Rabbit-1777, -1778, and -1779. All three sera were able to recognize 
the ~25KDa XPC fragment in BL21 whole cell lysate (Figure E3) to some degree. 
However, they were not competent for Western blot analysis of HSS extract (data not 
shown). In an effort to validate the specificity for XPC-1777 for Xenopus XPC protein, 
we used UV-irradiated Xenopus nuclei as a substrate to test whether the antibody has 
specificity for UV damaged chromatin using immunofluorescence. We found that XPC-
1777 specifically recognized nuclei irradiated with 1000 mJ/cm2 UV.  XPC has a well-
documented role in the binding and repair of UV lesions. Therefore, these results suggest 
that the XPC-1777 serum has specificity for XPC protein. However, further studies are 
needed to validate these preliminary results.  
Nevertheless, I tested whether the depletion of XPC using these antibodies would 
lead to an ICL repair defect in HSS. I found that in fact, the repair of trimethylene ICLs is 
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defective in HSS depleted with XPC-1777 serum (3 rounds of depletion 1:3:3 = beads : 
serum : HSS ratio, followed by a clearing round). This phenotype is more pronounced at 
earlier time points during repair (Figure E4A).  
Intriguingly, this ICL repair defect can be rescued with 5’ or 3’ nicked ICL plasmid 
substrates, suggesting that this defect was due to the loss of a protein that functions in an 
upstream role during the repair process (Figure E 4B). We did not attempt to clone and 
purify full length XPC protein from the cDNA library, and hence the specificity for the 




Figure E 2. XPC fragment used to generate X.l. XPC antibody 
Primers used to clone a 528 base pair fragment of X.l. XPC from the cDNA library are 
indicated. The DNA bases correspond to the sequenced product of the XPC fragment. 
This fragment was subsequently cloned into a bacterial expression vector and expressed 






Figure E 3. Homemade XPC antibodies recognize XPC528 in BL21 whole cell lysate 
Western blot of BL21 lysate from uninduced, or IPTG induced culture. All XPC sera 

































Figure E 4. XPC antibodies specifically recognize UV-damaged Xenopus nuclei 
Immunostaining of Xenopus nuclei using a commercial antibody against thymine dimer 
(TD) or XPC-1777 antibody. Both TD and XPC-1777 specifically recognize UV-














Figure E 5. XPC depletion results in defects in trimethylene ICL repair 
A. Upon depletion of XPC with XPC-1777 serum, the repair of trimethylene ICLs are 
significantly diminished at earlier timepoints.  
B. ICL repair defect in XPC depleted HSS can be rescued with 5’ or 3’ nicked ICL 
plasmid at 40 min.  
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